US20150030654A1 - PDLLA Stent Coating - Google Patents
PDLLA Stent Coating Download PDFInfo
- Publication number
- US20150030654A1 US20150030654A1 US14/259,458 US201414259458A US2015030654A1 US 20150030654 A1 US20150030654 A1 US 20150030654A1 US 201414259458 A US201414259458 A US 201414259458A US 2015030654 A1 US2015030654 A1 US 2015030654A1
- Authority
- US
- United States
- Prior art keywords
- stent
- coating
- composition
- solvent
- temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D1/00—Processes for applying liquids or other fluent materials
- B05D1/02—Processes for applying liquids or other fluent materials performed by spraying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
- A61F2002/3006—Properties of materials and coating materials
- A61F2002/30062—(bio)absorbable, biodegradable, bioerodable, (bio)resorbable, resorptive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
- A61F2002/3006—Properties of materials and coating materials
- A61F2002/30062—(bio)absorbable, biodegradable, bioerodable, (bio)resorbable, resorptive
- A61F2002/30064—Coating or prosthesis-covering structure made of biodegradable material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/02—Methods for coating medical devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/06—Coatings containing a mixture of two or more compounds
Definitions
- Blood vessel occlusions are commonly treated by mechanically en-hancing blood flow in the affected vessels, such as by employing a stent.
- Stents act as scaffoldings, functioning to physically hold open and, if desired, to expand the wall of the passageway.
- stents are capable of being compressed, so that they can be inserted through small lumens via catheters, and then expanded to a larger diameter once they are at the desired location. Examples in the patent literature disclosing stents include U.S. Pat. No. 4,733,665 issued to Palmaz, U.S. Pat. No. 4,800,882 issued to Gianturco, and U.S. Pat. No. 4,886,062 issued to Wiktor.
- FIG. 1 illustrates a conventional stent 10 formed from a plurality of struts 12 .
- the plurality of struts 12 are radially expandable and interconnected by connecting elements 14 that are disposed between adjacent struts 12 , leaving lateral openings or gaps 16 between adjacent struts 12 .
- Struts 12 and connecting elements 14 define a tubular stent body having an outer, tissue-contacting surface and an inner surface.
- Stents are used not only for mechanical intervention but also as vehi-cles for providing biological therapy.
- Biological therapy can be achieved by medicating the stents.
- Medicated stents provide for the local administration of a therapeutic substance at the diseased site. Local delivery of a therapeutic substance is a preferred method of treatment because the substance is concentrated at a specific site and thus smaller total levels of medication can be administered in comparison to systemic dos-ages that often produce adverse or even toxic side effects for the patient.
- One method of medicating a stent involves the use of a polymeric car-rier coated onto the surface of the stent.
- a composition including a solvent, a polymer dissolved in the solvent, and a therapeutic substance dispersed in the blend is applied to the stent by immersing the stent in the composition or by spraying the composition onto the stent.
- the solvent is allowed to evaporate, leaving on the stent strut surfaces a coating of the polymer and the therapeutic substance impregnated in the polymer.
- a shortcoming of the above-described method of medicating a stent is the potential for coating defects due to the large amount of liquid composition applied to the relatively small surface area of the stent.
- the liquid composition can flow, wick, and collect as the amount of composition on the stent increases during the coating process. As the solvent evaporates, the excess composition hardens, leaving the excess coating as clumps or pools on the struts or webbing between the struts.
- Another shortcoming of the above-described method of medicating a stent is the potential for loss of the therapeutic substance from the coating or produc-tion of a coating that does not provide for a suitable residence time of the substance at the implanted region.
- Initial portions of a liquid composition containing a therapeutic substance sprayed onto a stent adhere to the stent surface.
- layers of the composition are formed on top of one another.
- the therapeutic substance in the lower layers can be re-dissolved into the upper layers of the composition or extracted out from the coating.
- Having the therapeutic substance maintained in merely the upper regions of the coating provides for a short residence time of the substance at the implanted region, as the therapeutic substance will be quickly released. Prolonged residence times in situ may be desirable for a more effective treatment of a patient.
- the present invention addresses such problems by providing methods of coating implantable devices.
- a stent comprising a coating, the coating consisting of a poly(D,L-lactic acid) (PDLLA) and a macrocyclic drug, wherein the PDLLA has a degree of crystallinity of less than 20 percent, the measurement being by weight of the amount of polymer that is in the form of crystallites as measured by differential scanning calorimetry, wherein the coating has a thickness of 0.05 microns to 10 microns, and wherein the stent on which the coating is disposed is made from a bioabsorbably polymer.
- PDLLA poly(D,L-lactic acid)
- macrocyclic drug wherein the PDLLA has a degree of crystallinity of less than 20 percent, the measurement being by weight of the amount of polymer that is in the form of crystallites as measured by differential scanning calorimetry, wherein the coating has a thickness of 0.05 microns to 10 microns, and wherein the stent on which the coating is disposed is made from a bioabsorbably polymer
- FIG. 1 illustrates a conventional stent.
- the device or prosthesis coated in accordance with embodiments of the present invention may be any suitable medical substrate that can be implanted in a human or veterinary patient.
- implantable devices include self-expandable stents, balloon-expandable stents, stent-grafts, grafts (e.g., aortic grafts), artificial heart valves, cerebrospinal fluid shunts, pacemaker electrodes, and endocardial leads (e.g., FINELINE and ENDOTAK, available from Guidant Corporation).
- the underlying structure of the device can be of virtually any de-sign.
- the device can be made of a metallic material or an alloy such as, but not limited to, cobalt chromium alloy (ELGILOY), stainless steel (316L), high nitrogen stainless steel, e.g., BIODUR 108, cobalt chrome alloy L-605, “MP35N,” “MP20N,” ELASTINITE (Nitinol), tantalum, nickel-titanium alloy, platinum-iridium alloy, gold, magnesium, or combinations thereof.
- ELGILOY cobalt chromium alloy
- stainless steel 316L
- high nitrogen stainless steel e.g., BIODUR 108, cobalt chrome alloy L-605, “MP35N,” “MP20N,” ELASTINITE (Nitinol), tantalum, nickel-titanium alloy, platinum-iridium alloy, gold, magnesium, or combinations thereof.
- BIODUR 108 cobalt chrome alloy L-605, “MP35N,” “MP20N,” ELASTINITE (Nitinol)
- tantalum nickel-t
- MP35N consists of 35% cobalt, 35% nickel, 20% chromium, and 10% molybdenum.
- MP20N consists of 50% cobalt, 20% nickel, 20% chromium, and 10% molybdenum.
- Devices made from bioabsorbable or biosta-ble polymers could also be used with the embodiments of the present invention.
- the implantable device is chosen to specifically exclude any one or any combination of self-expandable stents, balloon-expandable stents, stent-grafts, grafts (e.g., aortic grafts), artificial heart valves, cerebrospinal fluid shunts, pacemaker electrodes, and endocardial leads (e.g., FINELINE and ENDOTAK, available from Guidant Corporation).
- the implantable device is not a catheter. In some embodiments in which the implantable device can be chosen to be a catheter, the implantable device is chosen not to be a catheter liner.
- the methods of some embodiments of the current invention comprise adjusting the temperature of an implantable portion of a medical device to a target temperature, which is always non-ambient, and then coating the implantable portion of the medical device with a coating substance.
- adjusting occurs such that the increase or decrease in temperature only occurs before applying the coating substance begins.
- adjusting occurs such that heating or cooling starts before and continues during the applying step or the adjusting and applying steps occur substantially together.
- the implantable device is adjusted to the target temperature before applying a coating substance and then applying occurs (with or without some amount of temperature decrease before crimping); alternatively, the implantable device is adjusted to the target temperature before applying a coating substance and maintained at or near the target temperature during applying; alternatively, applying is started, the implantable medical device is adjusted to the target temperature, and applying is completed. In some embodiments, applying begins before the implantable device has reached the target temperature and continues until or after the target temperature has been reached.
- ambient temperature is the temperature of the implantable device when it has not been purposely heated or cooled.
- ambient temperature is room temperature, 25-30° C., 20-30° C., 20-25° C., 23-27° C. or 10-30° C.
- a target temperature is a temperature numerically different from ambient temperature. In some embodiments, the difference between the target temperature and ambient is brought about by purposely heating or cooling the implantable device.
- a target temperature is chosen based on the characteristics of the components of the coating substance. For instance, if the solvent of the coating substance is non-volatile or has a low volatility, the target temperature can be chosen to be above ambient temperature to improve the evaporation rate. Conversely, if the coating substance solvent is volatile, the target temperature can be chosen to be below ambient temperature to lower the evaporation rate.
- the identity of the solvent is not the only characteristic upon which a target temperature can be based. For instance, if the coating substance comprises a therapeutic substance, the target temperature can be chosen to minimize thermal degradation of the therapeutic substance. Alternatively, if a polymer is used in the coating substance, the target temperature can be chosen above Tg of the polymer to improve its flow characteristics during deposition.
- the target temperature can be chosen to be above ambient temperature to improve the evaporation rate. Conversely, if the coating substance solvent has a low boiling point, the target temperature can be chosen to be below ambient temperature to lower the evaporation rate. Similarly, if the solvent is likely to freeze at ambient temperature during the applying step, the target temperature can be chosen to maintain it in a molten state to facilitate its removal.
- the target temperature is chosen to be above ambient temperature if the solvent is non-volatile or has low volatility.
- non-volatile and having low volatility take their standard meanings as rec-ognized by those of ordinary skill in the art.
- non-volatile and having low volatility means that the solvent has a volatility such that it does not substantially evaporate in a scientifically or commercially reasonable time as that time would be understood by one of ordinary skill in the art.
- non-volatile or having a low volatility means that when a solution composed of at least the solvent is applied to an implantable device the solvent does not substantially evaporate within 30 sec, 60 sec, 2 min, 5 min, 10 min, 15 min, 30 min, or 60 min at ambient temperature and pressure.
- the target temperature is chosen to be below ambient temperature if the solvent is volatile.
- volatile takes its standard meanings as rec-ognized by those of ordinary skill in the art. In these or other embodiments, volatile means the solvent substantially evaporates fast enough to compromise the coating in a scientifically or commercially unreasonable manner as that would be understood by one of ordinary skill in the art.
- volatile means that when a solution composed of at least the solvent is applied to an implantable device the solvent substantially evaporates within ⁇ 30 sec, ⁇ 20 sec, ⁇ 15 sec, ⁇ 10 sec, ⁇ 8 sec, ⁇ 5 sec, ⁇ 4 sec, ⁇ 3 sec, ⁇ 2 sec, or ⁇ 1 sec at ambient temperature and pressure.
- the target temperature is chosen to be below the decomposition region for a therapeutic substance.
- the target temperature can be chosen higher than ambient. In some embodiments that use coating substances to form topcoat layers, the target temperature can be chosen close to ambient or lower than ambient temperature.
- adjusting the temperature of the implantable device comprises adjusting the temperature to a target temperature and then letting the temperature fluctuate thereafter.
- adjusting the temperature of the implantable medical device to a target temperature means adjusting the temperature to within ⁇ 1° C., ⁇ 2° C., ⁇ 3° C., ⁇ 4° C., ⁇ 5° C., ⁇ 6° C., ⁇ 7° C., ⁇ 8° C., ⁇ 9° C., ⁇ 10° C., ⁇ 12° C., ⁇ 15° C., or ⁇ 20° C. of the target temperature before, during, or after the applying step begins.
- “Adjusting” the temperature of the medical device comprises placing the object that is to have its temperature adjusted into thermal contact with a heat source.
- thermal contact with a heat source means heat source arrangement vis-à-vis the object so that energy would flow or be carried from the heat source to the object.
- Thermal contact is a generic term at least encompassing an arrangement of the object such that radiation, conduction, or convection from the heat source would transfer energy. In some embodiments, thermal contact is defined to exclude any of radiation, conduction, convection, or any combination of these.
- no invention embodiments use a convection oven or an ultrasound energy source.
- “maintained near the target temperature” means that the temperature of the implantable device, when it contacts the coating substance, is the same as the target temperature or within ⁇ 1° C., ⁇ 2° C., ⁇ 3° C., ⁇ 4° C., ⁇ 5° C., ⁇ 6° C., ⁇ 7° C., ⁇ 8° C., ⁇ 9° C., ⁇ 10° C., ⁇ 12° C., ⁇ 15° C., or ⁇ 20° C. of the target temperature.
- “maintained at the target temperature during the applying step” means keeping the temperature of the implantable device the same as the target temperature or within ⁇ 1° C., ⁇ 2° C., ⁇ 3° C., ⁇ 4° C., ⁇ 5° C., ⁇ 6° C., ⁇ 7° C., ⁇ 8° C., ⁇ 9° C., ⁇ 10° C., ⁇ 12° C., ⁇ 15° C., or ⁇ 20° C. of the target temperature.
- the applying step forms a coating on an implantable medical device such as a stent; it is accomplished in some embodiments by spraying a composition onto the stent.
- a spray apparatus such as EFD 780S spray device with VALVEMATE 7040 control system (manufactured by EFD Inc., East Buffalo, R.I.), can be used to apply the composition to the stent.
- EFD 780S spray device is an air-assisted external mixing atomizer.
- the composition is atomized into small droplets by air and uniformly applied to the stent surfaces.
- the atomization pressure can be maintained at a range of about 5 psi to about 20 psi.
- the droplet size depends on factors such as vis-cosity of the solution, surface tension of the solvent, and atomization pressure.
- Other types of spray applicators including air-assisted internal mixing atomizers and ultrasonic applicators, can also be used for the application of the composition.
- the stent can be rotated about the stent's central longitudinal axis. Rotation of the stent can be from about 0.1 rpm to about 300 rpm, more narrowly from about 1 rpm to about 10 rpm. By way of example, the stent can rotate at about 3 rpm.
- the stent can also be moved in a linear direction along the same axis. The stent can be moved at about 1 mm/second to about 12 mm/second, for example about 6 mm/second, or for a minimum of at least two passes (i.e., back and forth past the spray nozzle).
- the flow rate of the composition from the spray nozzle can be from about 0.01 mg/second to about 1.0 mg/second, more narrowly about 0.1 mg/second. Only a small percentage of the composition that is delivered from the spray nozzle is ultimately deposited on the stent. By way of example, when a composition is sprayed to deliver about 1 mg of solids, only about 100 micrograms or about 10% of the solids sprayed will likely be deposited on the stent. Multiple repetitions for applying the composition can be performed, wherein each repetition can be, for example, about 0.5 second to about 5 seconds in duration. In these or other embodiments, the steps can be repeated 2-100, 2-50, 30-100, 20-50, 50-100, or greater than 100 times. The amount of coating applied by each repetition can be about 1 microgram/cm 2 (of stent surface) to about 50 micrograms/cm 2 , for example less than about 20 micrograms/cm 2 per 1-second spray.
- Each repetition can be followed by removal of a significant amount of the solvent(s).
- the removal of the solvent(s) can be performed following a waiting period of about 0.1 second to about 5 seconds after the application of the coating composition so as to allow the liquid sufficient time to flow and spread over the stent surface before the solvent(s) is removed to form a coating.
- the waiting period is particularly suitable if the coating composition contains a volatile solvent, such as solvents having boiling points >130° C. at ambient pressure, since such solvents are typically removed quickly.
- the applying step excludes immersing the temperature-adjusted implantable device into the coating substance.
- Removal of the solvent(s) can be induced by the application of a warm gas.
- the application of a warm gas between each repetition prevents coating defects and minimizes interaction between the active agent and the solvent.
- Any suitable gas can be employed, examples of which include air or nitrogen.
- the temperature of the warm gas can be from about 25° C. to about 200° C., more narrowly from about 40° C. to about 90° C.
- the flow speed of the gas can be from about 0.5 feet 3 /second (0.01 meters 3 /second) to about 50 feet 3 /second (1.42 meters 3 /second), more narrowly about 2.5 feet 3 /second (0.07 meters 3 /second) to about 15 feet 3 /second (0.43 meters 3 /second).
- the gas can be applied for about 1 second to about 100 seconds, more narrowly for about 2 seconds to about 20 seconds.
- warm gas applications can be performed at a temperature of about 60° C., at a flow speed of about 10 feet 3 /second, and for about 10 seconds.
- the stent can be warmed to a temperature of from about 35° C. to about 80° C. prior to the application of the coating composition so as to facilitate faster removal of the solvent(s).
- the particular temperature selected depends, at least in part, on the particular active agent employed in the coating composition.
- pre-heating of the stent prior to applying a composition containing actinomycin D should be performed at a temperature not greater than about 55° C.
- Pre-heating is particularly suitable for embodiments in which the solvent(s) employed in the coating composition has a high boiling point, i.e., volatile solvents having boiling points of, for example, >130° C. at ambient pressure (e.g., dimethylsulfoxide (DMSO), dimethylformamide (DMF), and dimethylacetamide (DMAC)).
- DMSO dimethylsulfoxide
- DMF dimethylformamide
- DMAC dimethylacetamide
- any suitable number of repetitions of applying the composition followed by removing the solvent(s) can be performed to form a coating of a desired thickness or weight. Excessive application of the polymer can, however, cause coating defects.
- a waiting period of from about 0.1 second to about 20 seconds can be employed between solvent removal of one repetition and composition application of the subsequent repetition so as to ensure that the wetting rate of the coating composition is slower than the evaporation rate of the solvent within the composition, thereby pro-moting coating uniformity.
- wiping refers to the physical removal of excess coating from the surface of the stent
- centrifugation refers to rapid rotation of the stent about an axis of rotation.
- the excess coating can also be vacuumed off of the surface of the stent.
- the stent can be at least partially pre-expanded prior to the application of the composition.
- the stent can be radially expanded about 20% to about 60%, more narrowly about 27% to about 55%—the measurement being taken from the stent's inner diameter at an expanded position as compared to the inner diameter at the unexpanded position.
- the expansion of the stent, for increasing the interspace between the stent struts during the application of the composition can further prevent “cob web” formation between the stent struts.
- a final heat treatment can be conducted to remove essentially all of the solvent(s) from the composition on the stent.
- the heat treatment can be conducted at about 30° C. to about 200° C. for about 15 minutes to about 16 hours, more narrowly at about 50° C. to about 100° C. for about 1 hour to about 4 hours. By way of example, the heat treatment can be conducted at about 75° C. for 1 hour.
- the temperature of ex-posure should not adversely affect the characteristics of the active agent or of the coating.
- the heating can be conducted in an anhydrous atmosphere and at ambient pressure. The heating can, alternatively, be conducted under a vacuum condition. It is understood that essentially all of the solvent(s) will be removed from the composition but traces or residues can remain blended in the coating.
- the coating referred to herein as the primary or reservoir coating
- the coating can have a thickness of about 0.05 microns to about 10 microns.
- the particular thickness of the coating is based on the type of procedure for which the stent is employed and the amount, if any, of active agent that is desired to be delivered. Applying a plurality of reservoir coating layers, containing the same or different active agents, onto the stent can further increase the amount of the active ingredient to be carried by the stent, without causing coating defects.
- the coating substance can include a solvent and a polymer dissolved in the solvent.
- the coating substance can also include active agents, radiopaque elements, or radioactive isotopes.
- Representative examples of polymers that can be used to coat a stent include ethylene vinyl alcohol copolymer (commonly known by the generic name EVOH or by the trade name EVAL), poly(hydroxyvalerate); poly(L-lactic acid); polycaprolactone; poly(lactide-co-glycolide); poly(hydroxybutyrate); poly(hydroxybutyrate-co-valerate); polydioxanone; polyorthoester; polyanhydride; poly(glycolic acid); poly(D,L-lactic acid); poly(glycolic acid-co-trimethylene carbonate); polyphosphoester; polyphosphoester urethane; poly(amino acids); cyanoacrylates; poly(trimethylene carbonate); poly(iminocarbonate); copoly(ether-esters) (e
- PEO/PLA polyalkylene oxalates; polyphosphazenes; biomolecules, such as fibrin, fibrinogen, cellulose, starch, collagen and hyaluronic acid; polyurethanes; silicones; polyesters; polyolefins; polyisobutylene and ethylene-alphaolefin copolymers; acrylic polymers and copolymers; vinyl halide polymers and copolymers, such as polyvinyl chloride; polyvinyl ethers, such as poly-vinyl methyl ether; polyvinylidene halides, such as polyvinylidene fluoride and polyvinylidene chloride; polyacrylonitrile; polyvinyl ketones; polyvinyl aromatics, such as polystyrene; polyvinyl esters, such as polyvinyl acetate; copolymers of vinyl mono-mers with each other and olefins, such as ethylene-methyl methacrylate copolymers,
- the polymer or the processing conditions of the method are selected such that the polymer is non-crystalline.
- a crystalline polymer is one in which upon analysis a detectable pattern may be observed when using conventional x-ray scattering techniques. Such conventional techniques are disclosed, for example, in “The Structure of Crystalline Polymers”, Tadokoro, H. (Wiley Inter-science, 1979).
- the degree of crystallinity of a polymer is the measurement by weight of the amount of polymer that is in the form of crystallites, as measured by differential scanning calorimetry. For purposes of this disclosure, a polymer that is non-crystalline has a degree of crystallinity of less than about 20 percent.
- solvent is defined as a liquid substance or composition that is compatible with the polymer and is capable of dissolving the polymer at the concentration desired in the composition.
- solvents include, but are not limited to, dimethylsulfoxide (DMSO), chloroform, acetone, water (buffered saline), xylene, methanol, ethanol, 1-propanol, tetrahydrofuran, 1-butanone, dimethylformamide, dimethylacetamide, cyclohexanone, ethyl acetate, methylethylketone, propylene glycol monomethylether, isopropanol, isopropanol admixed with water, N-methylpyrroli-dinone, toluene, and combinations thereof.
- the therapeutic agent can inhibit vascular, smooth muscle cell activi-ty. More specifically, the therapeutic agent can aim at inhibiting abnormal or inappro-priate migration or proliferation of smooth muscle cells to prevent, inhibit, reduce, or treat restenosis.
- the therapeutic agent can also include any substance capable of ex-erting a therapeutic or prophylactic effect in the practice of the present invention.
- Useful therapeutic agents can include therapeutic agents selected form antibiotics; anticoagulants; antifibrins; antiinflammatories; antimitotics; antineoplastics; antioxi-dants; antiplatelets; antiproliferatives; antithrombins; and their combinations.
- actinomycin D or derivatives and analogs thereof (manufactured by Sigma-Aldrich 1001 West Saint Paul Avenue, Milwaukee, Wis. 53233; or COSMEGEN available from Merck); dactinomycin; actinomycin IV; actinomycin I 1 ; actinomycin X 1 ; actinomycin C 1 ; paclitaxel; docetaxel; aspirin; sodium heparin; low molecular weight heparin; hirudin; argatroban; forskolin; vapiprost; prostacyclin; prostacyclin analogs; dextran; D-phe-pro-arg-chloromethylketone (synthetic antithrombin); dipyridamole; glycoprotein IIb/IIIa platelet membrane receptor antagonist; recombinant hirudin; thrombin inhibitor (available from Biogen); 7E-3B® (an antiplatelet drug from Centocor); methotrexate; azathioprin
- the therapeutic agent is selected to specifically exclude any one of or any combination of the therapeutic agents or therapeutic agent families described above.
- Some invention embodiments comprise a therapeutic agent or therapeutic agent combination, and some require a therapeutic agent or combination of therapeutic agents. Of the therapeutic agents specifically listed above, some invention embodiments exclude a single or any combination of these therapeutic agents.
- radiopaque elements include, but are not limited to, gold, tantalum, and platinum.
- An example of a radioactive isotope is P 32 .
- Sufficient amounts of such substances may be dispersed in the composition such that the substances are not present in the composition as agglomerates or flocs.
- the methods for coating an implantable device, such as a stent, according to embodiments of the present invention can be used to create a multi-layer structure that can include any one or any combination of the following four layers:
- a drug-polymer layer also referred to as “reservoir” or “reservoir layer” or a polymer-free drug layer
- a topcoat layer which is likewise drug containing or drug free.
- an optional primer layer can be formed prior to the primary or reservoir coating to increase the retention of the primary or reservoir coating on the surface of the stent, particularly metallic surfaces such as stainless steel.
- the primer layer can act as an intermediary adhesive tie layer between the surface of the device and a reservoir coating carrying an active agent, allowing for the quantity of the active agent to be increased in the reservoir coating.
- an embodiment of the above-described composition that is free from active agents is applied to the surface of the stent.
- Ethylene vinyl alcohol copolymer adheres very well to metallic surfaces, particularly stainless steel. Accordingly, the copolymer provides for a strong adhesive tie between the reservoir coating and the surface of the stent.
- the deposited primer composition should be exposed to a heat treatment at a temperature range greater than about the glass transition temperature (T g ) and less than about the melting temperature (T m ) of the selected polymer.
- T g glass transition temperature
- T m melting temperature
- the prosthesis should be exposed to the heat treatment for any suitable duration of time that will allow for the formation of the primer layer on the surface of the stent and for the evaporation of the solvent employed.
- the optional primer layer can have a thickness of about 0.01 microns to about 2 microns. The application of the primary or reservoir coating should be performed subsequent to the drying of the optional primer layer.
- an optional diffusion barrier can be formed over a reservoir coating containing an active agent to help control the rate at which the active agent is released from the coated stent.
- An embodiment of the composition, free from any active agents, can be applied to a selected portion of the primary or reservoir coating subsequent to the drying of the reservoir coating.
- Application of the composition and evaporation of the solvent to form the diffusion barrier can be accomplished via embodiments of the above-described method of the present invention.
- the diffusion barrier can have a thickness of about 0.2 microns to about 10 microns. It is understood by one of ordinary skill in the art that the thickness of the diffusion barrier is based on factors such as the type of stent, the type of procedure for which the stent is employed, and the rate of release that is desired.
- a final heat treatment can be conducted to remove essentially all of the solvent(s) from the optional diffusion barrier.
- Each unexpanded stent was positioned on a mandrel such that the mandrel contacted the stent at its opposing ends.
- An EFD 780S spray device with VALVEMATE 7040 control system (manufactured by EFD Inc., East Buffalo, R.I.) was used to apply the coating compositions to the stents.
- the spray nozzle was adjusted to provide a distance from the nozzle tip to the outer surface of the stent of approximately 4.5 cm and a spray angle of approximately 90° relative to the horizontal stents.
- the atomization pressure was set to be maintained throughout the coating process at 20 psi.
- Each stent was passed under the spray nozzle for about 2 seconds.
- a composition containing 2% (w/w) poly-n-butyl methacrylate (PBMA) 337K in cyclo-hexanone:ethyl acetate (1:1) was sprayed onto one stent.
- a composition containing 2% (w/w) PBMA 649K in cyclohexanone:ethyl acetate (1:1) was sprayed onto two stents.
- a composition containing 2% (w/w) PBMA 857K in cyclohexanone:ethyl acetate (1:1) was sprayed onto one stent.
- Each stent was rotated about the stent's central longitudinal axis at a speed of 3 rpm during coating. After a waiting period of 1 second following the application of the respective compositions, warm air of approximately 80° C. was directed from an air gun onto each stent for 15 seconds to remove most of the solvents. The spraying-blowing cycle was repeated to deposit thirty-four layers on each stent, with a wait time of 5 seconds between each cycle. The coated stent was allowed to dry for about 60 minutes under vacuum conditions in an oven at a temperature of about 70° C. Each of the four coated stents had a uniform, smooth coating.
- the stent sprayed with 2% (w/w) PBMA 857K in cyclohexa-none:ethyl acetate (1:1) was submitted for a simulated use test and was found to have good mechanical properties, no cracking, and good coating adhesion.
- An 8 mm Multi-Link TETRA stent was coated using embodiments of the method of the present invention.
- the stent was cleaned by placement in an ultrasonic bath of isopropyl alcohol solution for 15 minutes.
- the stent was dried and plasma cleaned in a plasma chamber.
- PBMA poly-n-butyl methacrylate
- quinoline yellow dye in chloroform:cyclohexanone (9:1) was prepared.
- the unexpanded stent was positioned on a mandrel such that the mandrel contacted the stent at its opposing ends.
- An EFD 780S spray device with VALVEMATE 7040 control system was used to apply the coating composition to the stent.
- the spray nozzle was adjusted to provide a distance from the nozzle tip to the outer surface of the stent of 1.25 inches (3.18 cm) and a spray angle of approximately 90° relative to the horizontal stent.
- the atomization pressure was set to be maintained throughout the coating process at 15 psi.
- the stent was passed under the spray nozzle for about 1 second.
- the stent was rotated about the stent's central longitudinal axis at a speed of 3 rpm during coating.
- Warm air of approximately 100° C. was directed from an air gun onto the stent for 4 seconds to remove most of the solvents.
- the spraying-heating cycle was repeated to deposit forty layers on the stent, depositing about 300 micrograms of coating.
- the coated stent was allowed to dry for about 3 hours under vacuum conditions at a temperature of about 75° C.
- the coated stent had a uniform, smooth coating with an estimated dye content of about 130 micrograms or 43% of the total amount of coating deposited.
- An 8 mm Multi-Link TETRA stent was coated using embodiments of the method of the present invention.
- the stent was cleaned by placement in an ultrasonic bath of isopropyl alcohol solution for 15 minutes.
- the stent was dried and plasma cleaned in a plasma chamber.
- a primer composition containing 2% (w/w) poly-n-butyl methacrylate (PBMA) was prepared.
- a reservoir composition containing 2% (w/w) PBMA and 2.7% (w/w) ethyl eosin dye in methanol:cyclohexanone (1:1) was also prepared.
- a diffusion barrier composition containing 2% (w/w) PBMA was prepared.
- the unexpanded stent was positioned on a mandrel such that the mandrel contacted the stent at its opposing ends.
- An EFD 780S spray device with VALVEMATE 7040 control system was used to apply the various compositions to the stent.
- the spray nozzle was adjusted to provide a distance from the nozzle tip to the outer surface of the stent of 1.25 inches (3.18 cm) and a spray angle of approximately 90° relative to the horizontal stent.
- the atomization pressure was set to be maintained throughout the coating process at 15 psi.
- the stent was rotated about the stent's central longitudinal axis at a speed of 3 rpm during coating.
- the primer composition was applied to the stent by passing the stent under the spray nozzle for about 0.75 second. Warm air of approximately 100° C. was directed from an air gun onto the stent for 8 seconds to remove most of the solvents and form a primer layer on the stent.
- the reservoir composition was then applied to the primered stent by passing the stent under the spray nozzle for about 0.75 second. Warm air of approximately 100° C. was directed from an air gun onto the stent for 4 seconds to remove most of the solvents.
- the spraying-heating cycle was repeated to deposit forty layers on the stent, depositing about 419 micrograms of the reservoir coating.
- the coated stent was allowed to dry for about 3 hours under vacuum conditions at a temperature of about 75° C.
- the barrier layer composition was then applied to the reservoir-coated stent by passing the stent under the spray nozzle for about 0.75 second. Warm air of approximately 100° C. was directed from an air gun onto the stent for 4 seconds to remove most of the solvents. The spraying-heating cycle was repeated to deposit about 70 micrograms of the diffusion barrier.
- the coated stent was allowed to dry overnight under vacuum conditions at a temperature of about 75° C.
- the coated stent had a uniform, smooth coating with an estimated dye content of about 224 micrograms or 53% of the total amount of coating deposited.
- An 8 mm Multi-Link TETRA stent was coated using embodiments of the method of the present invention.
- the stent was cleaned by placement in an ultrasonic bath of isopropyl alcohol solution for 15 minutes.
- the stent was dried and plasma cleaned in a plasma chamber.
- PBMA poly-n-butyl methacrylate
- quinoline yellow dye in chloroform:cyclohexanone (9:1) was prepared.
- the unexpanded stent was positioned on a mandrel such that the mandrel contacted the stent at its opposing ends.
- An EFD 780S spray device with VALVEMATE 7040 control system was used to apply the composition to the stent.
- the spray nozzle was adjusted to provide a distance from the nozzle tip to the outer surface of the stent of 1.25 inches (3.18 cm) and a spray angle of approximately 90° relative to the horizontal stent.
- the atomization pressure was set to be maintained throughout the coating process at 15 psi.
- the stent was passed under the spray nozzle for about 1.5 second.
- the stent was rotated about the stent's central longitudinal axis at a speed of 3 rpm during coating.
- Warm air of approximately 100° C. was directed from an air gun onto the stent for 4 seconds to remove most of the solvents.
- the spraying-heating cycle was repeated to deposit 3 layers on the stent, depositing about 115 micrograms of coating.
- the coated stent was allowed to dry for about 3 hours under vacuum conditions at a temperature of about 75° C.
- the coated stent had a uniform, smooth coating with an estimated dye content of about 38 micrograms or 33% of the total amount of coating deposited.
- a Multi-Link TETRA stent was coated using the same coating composition and parameters as described in Example 4. The spraying-heating cycle was repeated until 790 micrograms of coating had been deposited on the stent, at which time no webbing was observed.
- An 8 mm Multi-Link TETRA stent was coated using embodiments of the method of the present invention.
- the stent was cleaned by placement in an ultrasonic bath of isopropyl alcohol solution for 15 minutes.
- the stent was dried and plasma cleaned in a plasma chamber.
- a composition containing 2% (w/w) poly-n-butyl methacrylate (PBMA) and 2% (w/w) solvent blue dye in chloroform:cyclohexanone (9:1) was prepared.
- the unexpanded stent was positioned on a mandrel such that the mandrel contacted the stent at its opposing ends.
- An EFD 780S spray device with VALVEMATE 7040 control system was used to apply the composition to the stent.
- the spray nozzle was adjusted to provide a distance from the nozzle tip to the outer surface of the stent of 1.25 inches (3.18 cm) and a spray angle of approximately 90° relative to the horizontal stent.
- the atomization pressure was set to be maintained throughout the coating process at 15 psi.
- the stent was passed under the spray nozzle for about 1.5 seconds.
- the stent was rotated about the stent's central longitudinal axis at a speed of 3 rpm during coating.
- Warm air of approximately 100° C. was directed from an air gun onto the stent for 4 seconds to remove most of the solvents.
- the spraying-heating cycle was repeated to deposit about 130 micrograms of coating.
- the coated stent was allowed to dry for about 3 hours under vacuum conditions at a temperature of about 75° C.
- the coated stent had a uniform, smooth coating with a estimated dye content of about 85 micrograms or 66% of the total amount of coating deposited.
- ranges When this is done, it is meant to disclose the ranges as a range, and to disclose each and every point within the range, including end points.
- supplementary embodiments exist that are otherwise identical, but that specifically exclude the value or the conditions for the aspect.
Abstract
An amorphous PDLLA stent coating for drug delivery is disclosed.
Description
- This application is a continuation of application Ser. No. 11/022,228, filed on Dec. 23, 2004, which in turn is a continuation-in-part of application Ser. No. 09/894,293, filed on Jun. 27, 2001. The entire disclosures of both applications are incorporated into this document by reference.
- Blood vessel occlusions are commonly treated by mechanically en-hancing blood flow in the affected vessels, such as by employing a stent. Stents act as scaffoldings, functioning to physically hold open and, if desired, to expand the wall of the passageway. Typically stents are capable of being compressed, so that they can be inserted through small lumens via catheters, and then expanded to a larger diameter once they are at the desired location. Examples in the patent literature disclosing stents include U.S. Pat. No. 4,733,665 issued to Palmaz, U.S. Pat. No. 4,800,882 issued to Gianturco, and U.S. Pat. No. 4,886,062 issued to Wiktor.
-
FIG. 1 illustrates aconventional stent 10 formed from a plurality ofstruts 12. The plurality ofstruts 12 are radially expandable and interconnected by connectingelements 14 that are disposed betweenadjacent struts 12, leaving lateral openings orgaps 16 betweenadjacent struts 12.Struts 12 and connectingelements 14 define a tubular stent body having an outer, tissue-contacting surface and an inner surface. - Stents are used not only for mechanical intervention but also as vehi-cles for providing biological therapy. Biological therapy can be achieved by medicating the stents. Medicated stents provide for the local administration of a therapeutic substance at the diseased site. Local delivery of a therapeutic substance is a preferred method of treatment because the substance is concentrated at a specific site and thus smaller total levels of medication can be administered in comparison to systemic dos-ages that often produce adverse or even toxic side effects for the patient.
- One method of medicating a stent involves the use of a polymeric car-rier coated onto the surface of the stent. A composition including a solvent, a polymer dissolved in the solvent, and a therapeutic substance dispersed in the blend is applied to the stent by immersing the stent in the composition or by spraying the composition onto the stent. The solvent is allowed to evaporate, leaving on the stent strut surfaces a coating of the polymer and the therapeutic substance impregnated in the polymer.
- A shortcoming of the above-described method of medicating a stent is the potential for coating defects due to the large amount of liquid composition applied to the relatively small surface area of the stent. The liquid composition can flow, wick, and collect as the amount of composition on the stent increases during the coating process. As the solvent evaporates, the excess composition hardens, leaving the excess coating as clumps or pools on the struts or webbing between the struts.
- Another shortcoming of the above-described method of medicating a stent is the potential for loss of the therapeutic substance from the coating or produc-tion of a coating that does not provide for a suitable residence time of the substance at the implanted region. Initial portions of a liquid composition containing a therapeutic substance sprayed onto a stent adhere to the stent surface. However, as the liquid composition continues to be applied to the stent, layers of the composition are formed on top of one another. When exposed to the solvent in the upper layers, the therapeutic substance in the lower layers can be re-dissolved into the upper layers of the composition or extracted out from the coating. Having the therapeutic substance maintained in merely the upper regions of the coating provides for a short residence time of the substance at the implanted region, as the therapeutic substance will be quickly released. Prolonged residence times in situ may be desirable for a more effective treatment of a patient.
- The present invention addresses such problems by providing methods of coating implantable devices.
- A stent is disclosed comprising a coating, the coating consisting of a poly(D,L-lactic acid) (PDLLA) and a macrocyclic drug, wherein the PDLLA has a degree of crystallinity of less than 20 percent, the measurement being by weight of the amount of polymer that is in the form of crystallites as measured by differential scanning calorimetry, wherein the coating has a thickness of 0.05 microns to 10 microns, and wherein the stent on which the coating is disposed is made from a bioabsorbably polymer.
-
FIG. 1 illustrates a conventional stent. - This document incorporates by this reference the entire disclosure of U.S. patent application Ser. No. 09/894,293, which was filed on Jun. 27, 2001.
- For ease of discussion, the methods detailed herein will be described with reference to coating a stent. However, the device or prosthesis coated in accordance with embodiments of the present invention may be any suitable medical substrate that can be implanted in a human or veterinary patient. Examples of such implantable devices include self-expandable stents, balloon-expandable stents, stent-grafts, grafts (e.g., aortic grafts), artificial heart valves, cerebrospinal fluid shunts, pacemaker electrodes, and endocardial leads (e.g., FINELINE and ENDOTAK, available from Guidant Corporation). The underlying structure of the device can be of virtually any de-sign. The device can be made of a metallic material or an alloy such as, but not limited to, cobalt chromium alloy (ELGILOY), stainless steel (316L), high nitrogen stainless steel, e.g., BIODUR 108, cobalt chrome alloy L-605, “MP35N,” “MP20N,” ELASTINITE (Nitinol), tantalum, nickel-titanium alloy, platinum-iridium alloy, gold, magnesium, or combinations thereof. “MP35N” and “MP20N” are trade names for alloys of cobalt, nickel, chromium and molybdenum available from Standard Press Steel Co., Jenkintown, Pa. “MP35N” consists of 35% cobalt, 35% nickel, 20% chromium, and 10% molybdenum. “MP20N” consists of 50% cobalt, 20% nickel, 20% chromium, and 10% molybdenum. Devices made from bioabsorbable or biosta-ble polymers could also be used with the embodiments of the present invention. In some embodiments, the implantable device is chosen to specifically exclude any one or any combination of self-expandable stents, balloon-expandable stents, stent-grafts, grafts (e.g., aortic grafts), artificial heart valves, cerebrospinal fluid shunts, pacemaker electrodes, and endocardial leads (e.g., FINELINE and ENDOTAK, available from Guidant Corporation). In some embodiments, the implantable device is not a catheter. In some embodiments in which the implantable device can be chosen to be a catheter, the implantable device is chosen not to be a catheter liner.
- The methods of some embodiments of the current invention comprise adjusting the temperature of an implantable portion of a medical device to a target temperature, which is always non-ambient, and then coating the implantable portion of the medical device with a coating substance. In some embodiments, adjusting occurs such that the increase or decrease in temperature only occurs before applying the coating substance begins. In other embodiments, adjusting occurs such that heating or cooling starts before and continues during the applying step or the adjusting and applying steps occur substantially together.
- Different invention embodiments employ different “adjusting” profiles. For instance, in some profiles, the implantable device is adjusted to the target temperature before applying a coating substance and then applying occurs (with or without some amount of temperature decrease before crimping); alternatively, the implantable device is adjusted to the target temperature before applying a coating substance and maintained at or near the target temperature during applying; alternatively, applying is started, the implantable medical device is adjusted to the target temperature, and applying is completed. In some embodiments, applying begins before the implantable device has reached the target temperature and continues until or after the target temperature has been reached.
- For purposes of this disclosure, ambient temperature is the temperature of the implantable device when it has not been purposely heated or cooled. In al-ternative embodiments, ambient temperature is room temperature, 25-30° C., 20-30° C., 20-25° C., 23-27° C. or 10-30° C. Similarly, for purposes of this disclosure, a target temperature is a temperature numerically different from ambient temperature. In some embodiments, the difference between the target temperature and ambient is brought about by purposely heating or cooling the implantable device.
- A target temperature is chosen based on the characteristics of the components of the coating substance. For instance, if the solvent of the coating substance is non-volatile or has a low volatility, the target temperature can be chosen to be above ambient temperature to improve the evaporation rate. Conversely, if the coating substance solvent is volatile, the target temperature can be chosen to be below ambient temperature to lower the evaporation rate. The identity of the solvent is not the only characteristic upon which a target temperature can be based. For instance, if the coating substance comprises a therapeutic substance, the target temperature can be chosen to minimize thermal degradation of the therapeutic substance. Alternatively, if a polymer is used in the coating substance, the target temperature can be chosen above Tg of the polymer to improve its flow characteristics during deposition. In other embodiments, if the solvent of the coating substance has a high boiling point, the target temperature can be chosen to be above ambient temperature to improve the evaporation rate. Conversely, if the coating substance solvent has a low boiling point, the target temperature can be chosen to be below ambient temperature to lower the evaporation rate. Similarly, if the solvent is likely to freeze at ambient temperature during the applying step, the target temperature can be chosen to maintain it in a molten state to facilitate its removal. Those of ordinary skill in the art will be able to identify other characteristics of components of the coating substance that can be improved by applying the substances to an implantable device that is at a non-ambient target temperature.
- In some embodiments, the target temperature is chosen to be above ambient temperature if the solvent is non-volatile or has low volatility. In some embodiments, non-volatile and having low volatility take their standard meanings as rec-ognized by those of ordinary skill in the art. In these or other embodiments, non-volatile and having low volatility means that the solvent has a volatility such that it does not substantially evaporate in a scientifically or commercially reasonable time as that time would be understood by one of ordinary skill in the art.
- In some embodiments, non-volatile or having a low volatility means that when a solution composed of at least the solvent is applied to an implantable device the solvent does not substantially evaporate within 30 sec, 60 sec, 2 min, 5 min, 10 min, 15 min, 30 min, or 60 min at ambient temperature and pressure. In some embodiments, the target temperature is chosen to be below ambient temperature if the solvent is volatile. In some embodiments, volatile takes its standard meanings as rec-ognized by those of ordinary skill in the art. In these or other embodiments, volatile means the solvent substantially evaporates fast enough to compromise the coating in a scientifically or commercially unreasonable manner as that would be understood by one of ordinary skill in the art. In some embodiments, volatile means that when a solution composed of at least the solvent is applied to an implantable device the solvent substantially evaporates within <30 sec, <20 sec, <15 sec, <10 sec, <8 sec, <5 sec, <4 sec, <3 sec, <2 sec, or <1 sec at ambient temperature and pressure. In some embodiments, the target temperature is chosen to be below the decomposition region for a therapeutic substance.
- In some embodiments that use coating substances to form primer layers, the target temperature can be chosen higher than ambient. In some embodiments that use coating substances to form topcoat layers, the target temperature can be chosen close to ambient or lower than ambient temperature.
- In some embodiments, adjusting the temperature of the implantable device comprises adjusting the temperature to a target temperature and then letting the temperature fluctuate thereafter.
- In some embodiments, adjusting the temperature of the implantable medical device to a target temperature means adjusting the temperature to within ±1° C., ±2° C., ±3° C., ±4° C., ±5° C., ±6° C., ±7° C., ±8° C., ±9° C., ±10° C., ±12° C., ±15° C., or ±20° C. of the target temperature before, during, or after the applying step begins.
- “Adjusting” the temperature of the medical device comprises placing the object that is to have its temperature adjusted into thermal contact with a heat source. For purposes of this disclosure, thermal contact with a heat source means heat source arrangement vis-à-vis the object so that energy would flow or be carried from the heat source to the object. Thermal contact is a generic term at least encompassing an arrangement of the object such that radiation, conduction, or convection from the heat source would transfer energy. In some embodiments, thermal contact is defined to exclude any of radiation, conduction, convection, or any combination of these. Furthermore no invention embodiments use a convection oven or an ultrasound energy source.
- In some embodiments, “maintained near the target temperature” means that the temperature of the implantable device, when it contacts the coating substance, is the same as the target temperature or within ±1° C., ±2° C., ±3° C., ±4° C., ±5° C., ±6° C., ±7° C., ±8° C., ±9° C., ±10° C., ±12° C., ±15° C., or ±20° C. of the target temperature.
- In some embodiments, “maintained at the target temperature during the applying step” means keeping the temperature of the implantable device the same as the target temperature or within ±1° C., ±2° C., ±3° C., ±4° C., ±5° C., ±6° C., ±7° C., ±8° C., ±9° C., ±10° C., ±12° C., ±15° C., or ±20° C. of the target temperature.
- The applying step forms a coating on an implantable medical device such as a stent; it is accomplished in some embodiments by spraying a composition onto the stent. A spray apparatus, such as EFD 780S spray device with VALVEMATE 7040 control system (manufactured by EFD Inc., East Providence, R.I.), can be used to apply the composition to the stent. EFD 780S spray device is an air-assisted external mixing atomizer. The composition is atomized into small droplets by air and uniformly applied to the stent surfaces. The atomization pressure can be maintained at a range of about 5 psi to about 20 psi. The droplet size depends on factors such as vis-cosity of the solution, surface tension of the solvent, and atomization pressure. Other types of spray applicators, including air-assisted internal mixing atomizers and ultrasonic applicators, can also be used for the application of the composition.
- During the application of the composition, the stent can be rotated about the stent's central longitudinal axis. Rotation of the stent can be from about 0.1 rpm to about 300 rpm, more narrowly from about 1 rpm to about 10 rpm. By way of example, the stent can rotate at about 3 rpm. The stent can also be moved in a linear direction along the same axis. The stent can be moved at about 1 mm/second to about 12 mm/second, for example about 6 mm/second, or for a minimum of at least two passes (i.e., back and forth past the spray nozzle).
- The flow rate of the composition from the spray nozzle can be from about 0.01 mg/second to about 1.0 mg/second, more narrowly about 0.1 mg/second. Only a small percentage of the composition that is delivered from the spray nozzle is ultimately deposited on the stent. By way of example, when a composition is sprayed to deliver about 1 mg of solids, only about 100 micrograms or about 10% of the solids sprayed will likely be deposited on the stent. Multiple repetitions for applying the composition can be performed, wherein each repetition can be, for example, about 0.5 second to about 5 seconds in duration. In these or other embodiments, the steps can be repeated 2-100, 2-50, 30-100, 20-50, 50-100, or greater than 100 times. The amount of coating applied by each repetition can be about 1 microgram/cm2 (of stent surface) to about 50 micrograms/cm2, for example less than about 20 micrograms/cm2 per 1-second spray.
- Each repetition can be followed by removal of a significant amount of the solvent(s). The removal of the solvent(s) can be performed following a waiting period of about 0.1 second to about 5 seconds after the application of the coating composition so as to allow the liquid sufficient time to flow and spread over the stent surface before the solvent(s) is removed to form a coating. The waiting period is particularly suitable if the coating composition contains a volatile solvent, such as solvents having boiling points >130° C. at ambient pressure, since such solvents are typically removed quickly.
- The applying step excludes immersing the temperature-adjusted implantable device into the coating substance.
- Removal of the solvent(s) can be induced by the application of a warm gas. The application of a warm gas between each repetition prevents coating defects and minimizes interaction between the active agent and the solvent. Any suitable gas can be employed, examples of which include air or nitrogen. The temperature of the warm gas can be from about 25° C. to about 200° C., more narrowly from about 40° C. to about 90° C. The flow speed of the gas can be from about 0.5 feet3/second (0.01 meters3/second) to about 50 feet3/second (1.42 meters3/second), more narrowly about 2.5 feet3/second (0.07 meters3/second) to about 15 feet3/second (0.43 meters3/second). The gas can be applied for about 1 second to about 100 seconds, more narrowly for about 2 seconds to about 20 seconds. By way of example, warm gas applications can be performed at a temperature of about 60° C., at a flow speed of about 10 feet3/second, and for about 10 seconds.
- In one embodiment, the stent can be warmed to a temperature of from about 35° C. to about 80° C. prior to the application of the coating composition so as to facilitate faster removal of the solvent(s). The particular temperature selected depends, at least in part, on the particular active agent employed in the coating composition. By way of example, pre-heating of the stent prior to applying a composition containing actinomycin D should be performed at a temperature not greater than about 55° C. Pre-heating is particularly suitable for embodiments in which the solvent(s) employed in the coating composition has a high boiling point, i.e., volatile solvents having boiling points of, for example, >130° C. at ambient pressure (e.g., dimethylsulfoxide (DMSO), dimethylformamide (DMF), and dimethylacetamide (DMAC)).
- Any suitable number of repetitions of applying the composition followed by removing the solvent(s) can be performed to form a coating of a desired thickness or weight. Excessive application of the polymer can, however, cause coating defects. In embodiments in which the coating composition contains a volatile solvent, a waiting period of from about 0.1 second to about 20 seconds can be employed between solvent removal of one repetition and composition application of the subsequent repetition so as to ensure that the wetting rate of the coating composition is slower than the evaporation rate of the solvent within the composition, thereby pro-moting coating uniformity.
- Operations such as wiping, centrifugation, or other web clearing acts can also be performed to achieve a more uniform coating. Briefly, wiping refers to the physical removal of excess coating from the surface of the stent; and centrifugation refers to rapid rotation of the stent about an axis of rotation. The excess coating can also be vacuumed off of the surface of the stent.
- In accordance with one embodiment, the stent can be at least partially pre-expanded prior to the application of the composition. For example, the stent can be radially expanded about 20% to about 60%, more narrowly about 27% to about 55%—the measurement being taken from the stent's inner diameter at an expanded position as compared to the inner diameter at the unexpanded position. The expansion of the stent, for increasing the interspace between the stent struts during the application of the composition, can further prevent “cob web” formation between the stent struts.
- A final heat treatment can be conducted to remove essentially all of the solvent(s) from the composition on the stent. The heat treatment can be conducted at about 30° C. to about 200° C. for about 15 minutes to about 16 hours, more narrowly at about 50° C. to about 100° C. for about 1 hour to about 4 hours. By way of example, the heat treatment can be conducted at about 75° C. for 1 hour. The temperature of ex-posure should not adversely affect the characteristics of the active agent or of the coating. The heating can be conducted in an anhydrous atmosphere and at ambient pressure. The heating can, alternatively, be conducted under a vacuum condition. It is understood that essentially all of the solvent(s) will be removed from the composition but traces or residues can remain blended in the coating.
- By way of example, and not limitation, the coating, referred to herein as the primary or reservoir coating, can have a thickness of about 0.05 microns to about 10 microns. The particular thickness of the coating is based on the type of procedure for which the stent is employed and the amount, if any, of active agent that is desired to be delivered. Applying a plurality of reservoir coating layers, containing the same or different active agents, onto the stent can further increase the amount of the active ingredient to be carried by the stent, without causing coating defects.
- In accordance with one embodiment, the coating substance can include a solvent and a polymer dissolved in the solvent. The coating substance can also include active agents, radiopaque elements, or radioactive isotopes. Representative examples of polymers that can be used to coat a stent include ethylene vinyl alcohol copolymer (commonly known by the generic name EVOH or by the trade name EVAL), poly(hydroxyvalerate); poly(L-lactic acid); polycaprolactone; poly(lactide-co-glycolide); poly(hydroxybutyrate); poly(hydroxybutyrate-co-valerate); polydioxanone; polyorthoester; polyanhydride; poly(glycolic acid); poly(D,L-lactic acid); poly(glycolic acid-co-trimethylene carbonate); polyphosphoester; polyphosphoester urethane; poly(amino acids); cyanoacrylates; poly(trimethylene carbonate); poly(iminocarbonate); copoly(ether-esters) (e.g. PEO/PLA); polyalkylene oxalates; polyphosphazenes; biomolecules, such as fibrin, fibrinogen, cellulose, starch, collagen and hyaluronic acid; polyurethanes; silicones; polyesters; polyolefins; polyisobutylene and ethylene-alphaolefin copolymers; acrylic polymers and copolymers; vinyl halide polymers and copolymers, such as polyvinyl chloride; polyvinyl ethers, such as poly-vinyl methyl ether; polyvinylidene halides, such as polyvinylidene fluoride and polyvinylidene chloride; polyacrylonitrile; polyvinyl ketones; polyvinyl aromatics, such as polystyrene; polyvinyl esters, such as polyvinyl acetate; copolymers of vinyl mono-mers with each other and olefins, such as ethylene-methyl methacrylate copolymers, acrylonitrile-styrene copolymers, ABS resins, and ethylene-vinyl acetate copolymers; polyamides, such as Nylon 66 and polycaprolactam; alkyd resins; polycarbonates; polyoxymethylenes; polyimides; polyethers; epoxy resins; polyurethanes; rayon; ray-on-triacetate; cellulose; cellulose acetate; cellulose butyrate; cellulose acetate butyrate; cellophane; cellulose nitrate; cellulose propionate; cellulose ethers; and carboxymethyl cellulose.
- In some embodiments, the polymer or the processing conditions of the method are selected such that the polymer is non-crystalline. A crystalline polymer is one in which upon analysis a detectable pattern may be observed when using conventional x-ray scattering techniques. Such conventional techniques are disclosed, for example, in “The Structure of Crystalline Polymers”, Tadokoro, H. (Wiley Inter-science, 1979). The degree of crystallinity of a polymer is the measurement by weight of the amount of polymer that is in the form of crystallites, as measured by differential scanning calorimetry. For purposes of this disclosure, a polymer that is non-crystalline has a degree of crystallinity of less than about 20 percent.
- “Solvent” is defined as a liquid substance or composition that is compatible with the polymer and is capable of dissolving the polymer at the concentration desired in the composition. Examples of solvents include, but are not limited to, dimethylsulfoxide (DMSO), chloroform, acetone, water (buffered saline), xylene, methanol, ethanol, 1-propanol, tetrahydrofuran, 1-butanone, dimethylformamide, dimethylacetamide, cyclohexanone, ethyl acetate, methylethylketone, propylene glycol monomethylether, isopropanol, isopropanol admixed with water, N-methylpyrroli-dinone, toluene, and combinations thereof.
- The therapeutic agent can inhibit vascular, smooth muscle cell activi-ty. More specifically, the therapeutic agent can aim at inhibiting abnormal or inappro-priate migration or proliferation of smooth muscle cells to prevent, inhibit, reduce, or treat restenosis. The therapeutic agent can also include any substance capable of ex-erting a therapeutic or prophylactic effect in the practice of the present invention. Useful therapeutic agents can include therapeutic agents selected form antibiotics; anticoagulants; antifibrins; antiinflammatories; antimitotics; antineoplastics; antioxi-dants; antiplatelets; antiproliferatives; antithrombins; and their combinations. Other useful therapeutic agents include actinomycin D or derivatives and analogs thereof (manufactured by Sigma-Aldrich 1001 West Saint Paul Avenue, Milwaukee, Wis. 53233; or COSMEGEN available from Merck); dactinomycin; actinomycin IV; actinomycin I1; actinomycin X1; actinomycin C1; paclitaxel; docetaxel; aspirin; sodium heparin; low molecular weight heparin; hirudin; argatroban; forskolin; vapiprost; prostacyclin; prostacyclin analogs; dextran; D-phe-pro-arg-chloromethylketone (synthetic antithrombin); dipyridamole; glycoprotein IIb/IIIa platelet membrane receptor antagonist; recombinant hirudin; thrombin inhibitor (available from Biogen); 7E-3B® (an antiplatelet drug from Centocor); methotrexate; azathioprine; vincristine; vinblastine; fluorouracil; adriamycin; mutamycin; angiopeptin (a somatostatin analog from Ibsen); angiotensin converting enzyme inhibitors; CAPTOPRIL (available from Squibb); CI-LAZAPRIL (available from Hoffman-LaRoche); LISINOPRIL (available from Merck & Co., Whitehouse Station, N.J.); calcium channel blockers; Nifedipine; colchicinefib-roblast growth factor (FGF) antagonists; histamine antagonist; LOVASTATIN (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug from Merck & Co.); mon-oclonal antibodies (such as PDGF receptors); nitroprusside; phosphodiesterase inhibitors; prostaglandin inhibitor (available from Glazo); Seramin (a PDGF antagonist); serotonin blockers; thioprotease inhibitors; triazolopyrimidine (a PDGF antagonist); nitric oxide; alpha-interferon; genetically engineered epithelial cells; dexamethasone; estradiol; clobetasol propionate; cisplatin; insulin sensitizers; receptor tyrosine kinase inhibitors; carboplatin; Rapamycin; 40-O-(2-hydroxy)ethyl-rapamycin, or a functional analog or structural derivative thereof; 40-O-(3-hydroxy)propyl-rapamycin; 40-O-2-(2-hydroxy)ethoxyethyl-rapamycin and their combinations.
- Individual embodiments exist in which the therapeutic agent is selected to specifically exclude any one of or any combination of the therapeutic agents or therapeutic agent families described above.
- Some invention embodiments comprise a therapeutic agent or therapeutic agent combination, and some require a therapeutic agent or combination of therapeutic agents. Of the therapeutic agents specifically listed above, some invention embodiments exclude a single or any combination of these therapeutic agents.
- Examples of radiopaque elements include, but are not limited to, gold, tantalum, and platinum. An example of a radioactive isotope is P32. Sufficient amounts of such substances may be dispersed in the composition such that the substances are not present in the composition as agglomerates or flocs.
- The methods for coating an implantable device, such as a stent, according to embodiments of the present invention, can be used to create a multi-layer structure that can include any one or any combination of the following four layers:
- (a) a primer layer;
- (b) a drug-polymer layer (also referred to as “reservoir” or “reservoir layer”) or a polymer-free drug layer; and
- (c) a topcoat layer, which is likewise drug containing or drug free.
- (d) a finishing layer, for biocompatibility possessing biobeneficial properties.
- In some embodiment, an optional primer layer can be formed prior to the primary or reservoir coating to increase the retention of the primary or reservoir coating on the surface of the stent, particularly metallic surfaces such as stainless steel. The primer layer can act as an intermediary adhesive tie layer between the surface of the device and a reservoir coating carrying an active agent, allowing for the quantity of the active agent to be increased in the reservoir coating.
- To form an optional primer layer on the surface of the stent, an embodiment of the above-described composition that is free from active agents is applied to the surface of the stent. Ethylene vinyl alcohol copolymer, for example, adheres very well to metallic surfaces, particularly stainless steel. Accordingly, the copolymer provides for a strong adhesive tie between the reservoir coating and the surface of the stent. With the use of thermoplastic polymers such as, but not limited to, ethylene vinyl alcohol copolymer, polycaprolactone, poly(lactide-co-glycolide), and poly(hydroxybutyrate), the deposited primer composition should be exposed to a heat treatment at a temperature range greater than about the glass transition temperature (Tg) and less than about the melting temperature (Tm) of the selected polymer. Unex-pected results have been discovered with treatment of the composition under this temperature range, specifically strong adhesion or bonding of the coating to the metallic surface of the stent. The prosthesis should be exposed to the heat treatment for any suitable duration of time that will allow for the formation of the primer layer on the surface of the stent and for the evaporation of the solvent employed. By way of example and not limitation, the optional primer layer can have a thickness of about 0.01 microns to about 2 microns. The application of the primary or reservoir coating should be performed subsequent to the drying of the optional primer layer.
- In another embodiment, an optional diffusion barrier can be formed over a reservoir coating containing an active agent to help control the rate at which the active agent is released from the coated stent. An embodiment of the composition, free from any active agents, can be applied to a selected portion of the primary or reservoir coating subsequent to the drying of the reservoir coating. Application of the composition and evaporation of the solvent to form the diffusion barrier can be accomplished via embodiments of the above-described method of the present invention. The diffusion barrier can have a thickness of about 0.2 microns to about 10 microns. It is understood by one of ordinary skill in the art that the thickness of the diffusion barrier is based on factors such as the type of stent, the type of procedure for which the stent is employed, and the rate of release that is desired. As described above with reference to the primary or reservoir coating, a final heat treatment can be conducted to remove essentially all of the solvent(s) from the optional diffusion barrier.
- Either of the four layers or any combination of them can be formed using invention methods.
- The embodiments of the present invention will be illustrated by the following set forth examples, which are being given by way of illustration only and not by way of limitation. All parameters and data are not to be construed to unduly limit the scope of the embodiments of the invention.
- Four 8 mm Multi-Link TETRA stents (available from Guidant Corporation) were coated using embodiments of the method of the present invention. The stents were cleaned by sonication in water, followed by sonication in isopropanol. The stents were dried at 70° C. and plasma cleaned in an argon plasma chamber.
- Each unexpanded stent was positioned on a mandrel such that the mandrel contacted the stent at its opposing ends. An EFD 780S spray device with VALVEMATE 7040 control system (manufactured by EFD Inc., East Providence, R.I.) was used to apply the coating compositions to the stents. The spray nozzle was adjusted to provide a distance from the nozzle tip to the outer surface of the stent of approximately 4.5 cm and a spray angle of approximately 90° relative to the horizontal stents. The atomization pressure was set to be maintained throughout the coating process at 20 psi.
- Each stent was passed under the spray nozzle for about 2 seconds. A composition containing 2% (w/w) poly-n-butyl methacrylate (PBMA) 337K in cyclo-hexanone:ethyl acetate (1:1) was sprayed onto one stent. A composition containing 2% (w/w) PBMA 649K in cyclohexanone:ethyl acetate (1:1) was sprayed onto two stents. A composition containing 2% (w/w) PBMA 857K in cyclohexanone:ethyl acetate (1:1) was sprayed onto one stent. Each stent was rotated about the stent's central longitudinal axis at a speed of 3 rpm during coating. After a waiting period of 1 second following the application of the respective compositions, warm air of approximately 80° C. was directed from an air gun onto each stent for 15 seconds to remove most of the solvents. The spraying-blowing cycle was repeated to deposit thirty-four layers on each stent, with a wait time of 5 seconds between each cycle. The coated stent was allowed to dry for about 60 minutes under vacuum conditions in an oven at a temperature of about 70° C. Each of the four coated stents had a uniform, smooth coating. In addition, the stent sprayed with 2% (w/w) PBMA 857K in cyclohexa-none:ethyl acetate (1:1) was submitted for a simulated use test and was found to have good mechanical properties, no cracking, and good coating adhesion.
- An 8 mm Multi-Link TETRA stent was coated using embodiments of the method of the present invention. The stent was cleaned by placement in an ultrasonic bath of isopropyl alcohol solution for 15 minutes. The stent was dried and plasma cleaned in a plasma chamber.
- A composition containing 2% (w/w) poly-n-butyl methacrylate (PBMA) and 2% (w/w) quinoline yellow dye in chloroform:cyclohexanone (9:1) was prepared.
- The unexpanded stent was positioned on a mandrel such that the mandrel contacted the stent at its opposing ends. An EFD 780S spray device with VALVEMATE 7040 control system was used to apply the coating composition to the stent. The spray nozzle was adjusted to provide a distance from the nozzle tip to the outer surface of the stent of 1.25 inches (3.18 cm) and a spray angle of approximately 90° relative to the horizontal stent. The atomization pressure was set to be maintained throughout the coating process at 15 psi.
- The stent was passed under the spray nozzle for about 1 second. The stent was rotated about the stent's central longitudinal axis at a speed of 3 rpm during coating. Warm air of approximately 100° C. was directed from an air gun onto the stent for 4 seconds to remove most of the solvents. The spraying-heating cycle was repeated to deposit forty layers on the stent, depositing about 300 micrograms of coating. The coated stent was allowed to dry for about 3 hours under vacuum conditions at a temperature of about 75° C. The coated stent had a uniform, smooth coating with an estimated dye content of about 130 micrograms or 43% of the total amount of coating deposited.
- An 8 mm Multi-Link TETRA stent was coated using embodiments of the method of the present invention. The stent was cleaned by placement in an ultrasonic bath of isopropyl alcohol solution for 15 minutes. The stent was dried and plasma cleaned in a plasma chamber.
- A primer composition containing 2% (w/w) poly-n-butyl methacrylate (PBMA) was prepared. A reservoir composition containing 2% (w/w) PBMA and 2.7% (w/w) ethyl eosin dye in methanol:cyclohexanone (1:1) was also prepared. In addition, a diffusion barrier composition containing 2% (w/w) PBMA was prepared.
- The unexpanded stent was positioned on a mandrel such that the mandrel contacted the stent at its opposing ends. An EFD 780S spray device with VALVEMATE 7040 control system was used to apply the various compositions to the stent. The spray nozzle was adjusted to provide a distance from the nozzle tip to the outer surface of the stent of 1.25 inches (3.18 cm) and a spray angle of approximately 90° relative to the horizontal stent. The atomization pressure was set to be maintained throughout the coating process at 15 psi. The stent was rotated about the stent's central longitudinal axis at a speed of 3 rpm during coating.
- The primer composition was applied to the stent by passing the stent under the spray nozzle for about 0.75 second. Warm air of approximately 100° C. was directed from an air gun onto the stent for 8 seconds to remove most of the solvents and form a primer layer on the stent. The reservoir composition was then applied to the primered stent by passing the stent under the spray nozzle for about 0.75 second. Warm air of approximately 100° C. was directed from an air gun onto the stent for 4 seconds to remove most of the solvents. The spraying-heating cycle was repeated to deposit forty layers on the stent, depositing about 419 micrograms of the reservoir coating. The coated stent was allowed to dry for about 3 hours under vacuum conditions at a temperature of about 75° C. The barrier layer composition was then applied to the reservoir-coated stent by passing the stent under the spray nozzle for about 0.75 second. Warm air of approximately 100° C. was directed from an air gun onto the stent for 4 seconds to remove most of the solvents. The spraying-heating cycle was repeated to deposit about 70 micrograms of the diffusion barrier. The coated stent was allowed to dry overnight under vacuum conditions at a temperature of about 75° C. The coated stent had a uniform, smooth coating with an estimated dye content of about 224 micrograms or 53% of the total amount of coating deposited.
- An 8 mm Multi-Link TETRA stent was coated using embodiments of the method of the present invention. The stent was cleaned by placement in an ultrasonic bath of isopropyl alcohol solution for 15 minutes. The stent was dried and plasma cleaned in a plasma chamber.
- A composition containing 2% (w/w) poly-n-butyl methacrylate (PBMA) and 2% (w/w) quinoline yellow dye in chloroform:cyclohexanone (9:1) was prepared.
- The unexpanded stent was positioned on a mandrel such that the mandrel contacted the stent at its opposing ends. An EFD 780S spray device with VALVEMATE 7040 control system was used to apply the composition to the stent. The spray nozzle was adjusted to provide a distance from the nozzle tip to the outer surface of the stent of 1.25 inches (3.18 cm) and a spray angle of approximately 90° relative to the horizontal stent. The atomization pressure was set to be maintained throughout the coating process at 15 psi.
- The stent was passed under the spray nozzle for about 1.5 second. The stent was rotated about the stent's central longitudinal axis at a speed of 3 rpm during coating. Warm air of approximately 100° C. was directed from an air gun onto the stent for 4 seconds to remove most of the solvents. The spraying-heating cycle was repeated to deposit 3 layers on the stent, depositing about 115 micrograms of coating. The coated stent was allowed to dry for about 3 hours under vacuum conditions at a temperature of about 75° C. The coated stent had a uniform, smooth coating with an estimated dye content of about 38 micrograms or 33% of the total amount of coating deposited.
- To determine the maximum amount of coating that could be deposited on an 8 mm stent without visible webbing, a Multi-Link TETRA stent was coated using the same coating composition and parameters as described in Example 4. The spraying-heating cycle was repeated until 790 micrograms of coating had been deposited on the stent, at which time no webbing was observed.
- An 8 mm Multi-Link TETRA stent was coated using embodiments of the method of the present invention. The stent was cleaned by placement in an ultrasonic bath of isopropyl alcohol solution for 15 minutes. The stent was dried and plasma cleaned in a plasma chamber.
- A composition containing 2% (w/w) poly-n-butyl methacrylate (PBMA) and 2% (w/w) solvent blue dye in chloroform:cyclohexanone (9:1) was prepared.
- The unexpanded stent was positioned on a mandrel such that the mandrel contacted the stent at its opposing ends. An EFD 780S spray device with VALVEMATE 7040 control system was used to apply the composition to the stent. The spray nozzle was adjusted to provide a distance from the nozzle tip to the outer surface of the stent of 1.25 inches (3.18 cm) and a spray angle of approximately 90° relative to the horizontal stent. The atomization pressure was set to be maintained throughout the coating process at 15 psi.
- The stent was passed under the spray nozzle for about 1.5 seconds. The stent was rotated about the stent's central longitudinal axis at a speed of 3 rpm during coating. Warm air of approximately 100° C. was directed from an air gun onto the stent for 4 seconds to remove most of the solvents. The spraying-heating cycle was repeated to deposit about 130 micrograms of coating. The coated stent was allowed to dry for about 3 hours under vacuum conditions at a temperature of about 75° C. The coated stent had a uniform, smooth coating with a estimated dye content of about 85 micrograms or 66% of the total amount of coating deposited.
- While particular embodiments of the present invention have been shown and described, it will be obvious to those skilled in the art that changes and modifications can be made without departing from the embodiments of this invention in its broader aspects and, therefore, the appended claims are to encompass within their scope all such changes and modifications as fall within the true spirit and scope of the embodiments of this invention. Additionally, various embodiments have been described above. For convenience's sake, combinations of aspects (such as monomer type or gas flow rate) composing invention embodiments have been listed in such a way that one of ordinary skill in the art may read them exclusive of each other when they are not necessarily intended to be exclusive. But a recitation of an aspect for one embodiment is meant to disclose its use in all embodiments in which that aspect can be incorporated without undue experimentation. In like manner, a recitation of an aspect as composing part of an embodiment is a tacit recognition that a supplementary embodiment exists that specifically excludes that aspect.
- Moreover, some embodiments recite ranges. When this is done, it is meant to disclose the ranges as a range, and to disclose each and every point within the range, including end points. For those embodiments that disclose a specific value or condition for an aspect, supplementary embodiments exist that are otherwise identical, but that specifically exclude the value or the conditions for the aspect.
Claims (2)
1. A stent comprising a coating, the coating consisting of a poly(D,L-lactic acid) (PDLLA) and a macrocyclic drug, wherein the PDLLA has a degree of crystallinity of less than 20 percent, the measurement being by weight of the amount of polymer that is in the form of crystallites as measured by differential scanning calorimetry, wherein the coating has a thickness of 0.05 microns to 10 microns, and wherein the stent on which the coating is disposed is made from a bioabsorbable polymer.
2. The stent of claim 1 , wherein the drug is rapamycin.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/259,458 US20150030654A1 (en) | 2001-06-27 | 2014-04-23 | PDLLA Stent Coating |
US14/832,889 US10064982B2 (en) | 2001-06-27 | 2015-08-21 | PDLLA stent coating |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89429301A | 2001-06-27 | 2001-06-27 | |
US11/022,228 US8741378B1 (en) | 2001-06-27 | 2004-12-23 | Methods of coating an implantable device |
US14/259,458 US20150030654A1 (en) | 2001-06-27 | 2014-04-23 | PDLLA Stent Coating |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/022,228 Continuation US8741378B1 (en) | 2001-06-27 | 2004-12-23 | Methods of coating an implantable device |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/832,889 Continuation US10064982B2 (en) | 2001-06-27 | 2015-08-21 | PDLLA stent coating |
Publications (1)
Publication Number | Publication Date |
---|---|
US20150030654A1 true US20150030654A1 (en) | 2015-01-29 |
Family
ID=50781196
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/022,228 Expired - Fee Related US8741378B1 (en) | 2001-06-27 | 2004-12-23 | Methods of coating an implantable device |
US14/259,458 Abandoned US20150030654A1 (en) | 2001-06-27 | 2014-04-23 | PDLLA Stent Coating |
US14/832,889 Expired - Fee Related US10064982B2 (en) | 2001-06-27 | 2015-08-21 | PDLLA stent coating |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/022,228 Expired - Fee Related US8741378B1 (en) | 2001-06-27 | 2004-12-23 | Methods of coating an implantable device |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/832,889 Expired - Fee Related US10064982B2 (en) | 2001-06-27 | 2015-08-21 | PDLLA stent coating |
Country Status (1)
Country | Link |
---|---|
US (3) | US8741378B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018204289A1 (en) * | 2017-05-01 | 2018-11-08 | 480 Biomedical, Inc. | Drug-eluting medical implants |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8741378B1 (en) * | 2001-06-27 | 2014-06-03 | Advanced Cardiovascular Systems, Inc. | Methods of coating an implantable device |
US8685433B2 (en) | 2010-03-31 | 2014-04-01 | Abbott Cardiovascular Systems Inc. | Absorbable coating for implantable device |
CN104644295B (en) * | 2014-12-19 | 2019-07-16 | 上海百心安生物技术有限公司 | A kind of absorbable intraluminal stent and preparation method thereof |
KR102231249B1 (en) * | 2018-08-03 | 2021-03-23 | 오스템카디오텍 주식회사 | Stent preparing method of the same for suppressing webbing event |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6096070A (en) * | 1995-06-07 | 2000-08-01 | Med Institute Inc. | Coated implantable medical device |
US6153252A (en) * | 1998-06-30 | 2000-11-28 | Ethicon, Inc. | Process for coating stents |
US20030219562A1 (en) * | 2002-02-15 | 2003-11-27 | Frantisek Rypacek | Polymer coating for medical devices |
Family Cites Families (354)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR732895A (en) | 1932-10-18 | 1932-09-25 | Consortium Elektrochem Ind | Articles spun in polyvinyl alcohol |
US2386454A (en) | 1940-11-22 | 1945-10-09 | Bell Telephone Labor Inc | High molecular weight linear polyester-amides |
US3849514A (en) | 1967-11-17 | 1974-11-19 | Eastman Kodak Co | Block polyester-polyamide copolymers |
US3773737A (en) | 1971-06-09 | 1973-11-20 | Sutures Inc | Hydrolyzable polymers of amino acid and hydroxy acids |
US3882816A (en) | 1972-09-22 | 1975-05-13 | Western Electric Co | Apparatus for forming layers of fusible metal on articles |
US3995075A (en) | 1974-04-18 | 1976-11-30 | Continental Can Company, Inc. | Inside stripe by intermittent exterior spray guns |
US4329383A (en) | 1979-07-24 | 1982-05-11 | Nippon Zeon Co., Ltd. | Non-thrombogenic material comprising substrate which has been reacted with heparin |
SU790725A1 (en) | 1979-07-27 | 1983-01-23 | Ордена Ленина Институт Элементоорганических Соединений Ан Ссср | Process for preparing alkylaromatic polyimides |
US4226243A (en) | 1979-07-27 | 1980-10-07 | Ethicon, Inc. | Surgical devices of polyesteramides derived from bis-oxamidodiols and dicarboxylic acids |
SU811750A1 (en) | 1979-08-07 | 1983-09-23 | Институт Физиологии Им.С.И.Бериташвили | Bis-bicarbonates of aliphatic diols as monomers for preparing polyurethanes and process for producing the same |
SU872531A1 (en) | 1979-08-07 | 1981-10-15 | Институт Физиологии Им.И.С.Бериташвили Ан Гсср | Method of producing polyurethans |
SU876663A1 (en) | 1979-11-11 | 1981-10-30 | Институт Физиологии Им. Академика И.С.Бериташвили Ан Гсср | Method of producing polyarylates |
US4343931A (en) | 1979-12-17 | 1982-08-10 | Minnesota Mining And Manufacturing Company | Synthetic absorbable surgical devices of poly(esteramides) |
SU1016314A1 (en) | 1979-12-17 | 1983-05-07 | Институт Физиологии Им.И.С.Бериташвили | Process for producing polyester urethanes |
US4529792A (en) | 1979-12-17 | 1985-07-16 | Minnesota Mining And Manufacturing Company | Process for preparing synthetic absorbable poly(esteramides) |
SU905228A1 (en) | 1980-03-06 | 1982-02-15 | Институт Физиологии Им. Акад.И.С. Бериташвили Ан Гсср | Method for preparing thiourea |
US4560374A (en) | 1983-10-17 | 1985-12-24 | Hammerslag Julius G | Method for repairing stenotic vessels |
SU1293518A1 (en) | 1985-04-11 | 1987-02-28 | Тбилисский зональный научно-исследовательский и проектный институт типового и экспериментального проектирования жилых и общественных зданий | Installation for testing specimen of cross-shaped structure |
US4656242A (en) | 1985-06-07 | 1987-04-07 | Henkel Corporation | Poly(ester-amide) compositions |
US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
US4611051A (en) | 1985-12-31 | 1986-09-09 | Union Camp Corporation | Novel poly(ester-amide) hot-melt adhesives |
US4882168A (en) | 1986-09-05 | 1989-11-21 | American Cyanamid Company | Polyesters containing alkylene oxide blocks as drug delivery systems |
JPH0696023B2 (en) | 1986-11-10 | 1994-11-30 | 宇部日東化成株式会社 | Artificial blood vessel and method for producing the same |
US5721131A (en) | 1987-03-06 | 1998-02-24 | United States Of America As Represented By The Secretary Of The Navy | Surface modification of polymers with self-assembled monolayers that promote adhesion, outgrowth and differentiation of biological cells |
US4800882A (en) | 1987-03-13 | 1989-01-31 | Cook Incorporated | Endovascular stent and delivery system |
US6387379B1 (en) | 1987-04-10 | 2002-05-14 | University Of Florida | Biofunctional surface modified ocular implants, surgical instruments, medical devices, prostheses, contact lenses and the like |
US4894231A (en) | 1987-07-28 | 1990-01-16 | Biomeasure, Inc. | Therapeutic agent delivery system |
US4886062A (en) | 1987-10-19 | 1989-12-12 | Medtronic, Inc. | Intravascular radially expandable stent and method of implant |
US5019096A (en) | 1988-02-11 | 1991-05-28 | Trustees Of Columbia University In The City Of New York | Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same |
JP2561309B2 (en) | 1988-03-28 | 1996-12-04 | テルモ株式会社 | Medical material and manufacturing method thereof |
US4865879A (en) | 1988-03-31 | 1989-09-12 | Gordon Finlay | Method for restoring and reinforcing wooden structural component |
US4931287A (en) | 1988-06-14 | 1990-06-05 | University Of Utah | Heterogeneous interpenetrating polymer networks for the controlled release of drugs |
US5444113A (en) * | 1988-08-08 | 1995-08-22 | Ecopol, Llc | End use applications of biodegradable polymers |
US5328471A (en) | 1990-02-26 | 1994-07-12 | Endoluminal Therapeutics, Inc. | Method and apparatus for treatment of focal disease in hollow tubular organs and other tissue lumens |
US4977901A (en) | 1988-11-23 | 1990-12-18 | Minnesota Mining And Manufacturing Company | Article having non-crosslinked crystallized polymer coatings |
IL90193A (en) | 1989-05-04 | 1993-02-21 | Biomedical Polymers Int | Polurethane-based polymeric materials and biomedical articles and pharmaceutical compositions utilizing the same |
US5272012A (en) | 1989-06-23 | 1993-12-21 | C. R. Bard, Inc. | Medical apparatus having protective, lubricious coating |
US5971954A (en) | 1990-01-10 | 1999-10-26 | Rochester Medical Corporation | Method of making catheter |
WO1991011176A1 (en) | 1990-01-30 | 1991-08-08 | Akzo N.V. | Article for the controlled delivery of an active substance, comprising a hollow space fully enclosed by a wall and filled in full or in part with one or more active substances |
EP0518940A4 (en) | 1990-02-26 | 1993-05-12 | Marvin J. Slepian | Method and apparatus for treatment of tubular organs |
US5300295A (en) | 1990-05-01 | 1994-04-05 | Mediventures, Inc. | Ophthalmic drug delivery with thermoreversible polyoxyalkylene gels adjustable for pH |
US5292516A (en) | 1990-05-01 | 1994-03-08 | Mediventures, Inc. | Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers |
US5306501A (en) | 1990-05-01 | 1994-04-26 | Mediventures, Inc. | Drug delivery by injection with thermoreversible gels containing polyoxyalkylene copolymers |
US5298260A (en) | 1990-05-01 | 1994-03-29 | Mediventures, Inc. | Topical drug delivery with polyoxyalkylene polymer thermoreversible gels adjustable for pH and osmolality |
AU7998091A (en) | 1990-05-17 | 1991-12-10 | Harbor Medical Devices, Inc. | Medical device polymer |
ATE123658T1 (en) | 1990-06-15 | 1995-06-15 | Cortrak Medical Inc | DEVICE FOR DISPENSING MEDICATIONS. |
CA2038605C (en) | 1990-06-15 | 2000-06-27 | Leonard Pinchuk | Crack-resistant polycarbonate urethane polymer prostheses and the like |
US6060451A (en) | 1990-06-15 | 2000-05-09 | The National Research Council Of Canada | Thrombin inhibitors based on the amino acid sequence of hirudin |
US5112457A (en) | 1990-07-23 | 1992-05-12 | Case Western Reserve University | Process for producing hydroxylated plasma-polymerized films and the use of the films for enhancing the compatiblity of biomedical implants |
US5455040A (en) | 1990-07-26 | 1995-10-03 | Case Western Reserve University | Anticoagulant plasma polymer-modified substrate |
US6248129B1 (en) | 1990-09-14 | 2001-06-19 | Quanam Medical Corporation | Expandable polymeric stent with memory and delivery apparatus and method |
US5163952A (en) | 1990-09-14 | 1992-11-17 | Michael Froix | Expandable polymeric stent with memory and delivery apparatus and method |
US5258020A (en) | 1990-09-14 | 1993-11-02 | Michael Froix | Method of using expandable polymeric stent with memory |
US5462990A (en) | 1990-10-15 | 1995-10-31 | Board Of Regents, The University Of Texas System | Multifunctional organic polymers |
US5130173A (en) * | 1990-11-08 | 1992-07-14 | General Motors Corporation | Quick drying painting method where the paint and the object to be painted are both preheated |
GB9027793D0 (en) | 1990-12-21 | 1991-02-13 | Ucb Sa | Polyester-amides containing terminal carboxyl groups |
US5330768A (en) | 1991-07-05 | 1994-07-19 | Massachusetts Institute Of Technology | Controlled drug delivery using polymer/pluronic blends |
US5573934A (en) | 1992-04-20 | 1996-11-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
US5599352A (en) | 1992-03-19 | 1997-02-04 | Medtronic, Inc. | Method of making a drug eluting stent |
GB9206736D0 (en) | 1992-03-27 | 1992-05-13 | Sandoz Ltd | Improvements of organic compounds and their use in pharmaceutical compositions |
US5219980A (en) | 1992-04-16 | 1993-06-15 | Sri International | Polymers biodegradable or bioerodiable into amino acids |
DE69325845T2 (en) | 1992-04-28 | 2000-01-05 | Terumo Corp | Thermoplastic polymer composition and medical devices made therefrom |
DE4224401A1 (en) | 1992-07-21 | 1994-01-27 | Pharmatech Gmbh | New biodegradable homo- and co-polymer(s) for pharmaceutical use - produced by polycondensation of prod. from heterolytic cleavage of aliphatic polyester with functionalised (cyclo)aliphatic cpd. |
US5399665A (en) | 1992-11-05 | 1995-03-21 | Massachusetts Institute Of Technology | Biodegradable polymers for cell transplantation |
FR2699168B1 (en) | 1992-12-11 | 1995-01-13 | Rhone Poulenc Chimie | Method of treating a material comprising a polymer by hydrolysis. |
EP0604022A1 (en) | 1992-12-22 | 1994-06-29 | Advanced Cardiovascular Systems, Inc. | Multilayered biodegradable stent and method for its manufacture |
US5443458A (en) | 1992-12-22 | 1995-08-22 | Advanced Cardiovascular Systems, Inc. | Multilayered biodegradable stent and method of manufacture |
US20020055710A1 (en) | 1998-04-30 | 2002-05-09 | Ronald J. Tuch | Medical device for delivering a therapeutic agent and method of preparation |
US5824048A (en) | 1993-04-26 | 1998-10-20 | Medtronic, Inc. | Method for delivering a therapeutic substance to a body lumen |
US5464650A (en) | 1993-04-26 | 1995-11-07 | Medtronic, Inc. | Intravascular stent and method |
JPH0767895A (en) | 1993-06-25 | 1995-03-14 | Sumitomo Electric Ind Ltd | Antimicrobial artificial blood vessel and suture yarn for antimicrobial operation |
US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
EG20321A (en) | 1993-07-21 | 1998-10-31 | Otsuka Pharma Co Ltd | Medical material and process for producing the same |
DE4327024A1 (en) | 1993-08-12 | 1995-02-16 | Bayer Ag | Thermoplastically processable and biodegradable aliphatic polyesteramides |
US5380299A (en) | 1993-08-30 | 1995-01-10 | Med Institute, Inc. | Thrombolytic treated intravascular medical device |
WO1995010989A1 (en) | 1993-10-19 | 1995-04-27 | Scimed Life Systems, Inc. | Intravascular stent pump |
US5723004A (en) | 1993-10-21 | 1998-03-03 | Corvita Corporation | Expandable supportive endoluminal grafts |
US5759205A (en) | 1994-01-21 | 1998-06-02 | Brown University Research Foundation | Negatively charged polymeric electret implant |
US6051576A (en) | 1994-01-28 | 2000-04-18 | University Of Kentucky Research Foundation | Means to achieve sustained release of synergistic drugs by conjugation |
WO1995024929A2 (en) | 1994-03-15 | 1995-09-21 | Brown University Research Foundation | Polymeric gene delivery system |
US5567410A (en) | 1994-06-24 | 1996-10-22 | The General Hospital Corporation | Composotions and methods for radiographic imaging |
US5670558A (en) | 1994-07-07 | 1997-09-23 | Terumo Kabushiki Kaisha | Medical instruments that exhibit surface lubricity when wetted |
US5788979A (en) | 1994-07-22 | 1998-08-04 | Inflow Dynamics Inc. | Biodegradable coating with inhibitory properties for application to biocompatible materials |
US5516881A (en) | 1994-08-10 | 1996-05-14 | Cornell Research Foundation, Inc. | Aminoxyl-containing radical spin labeling in polymers and copolymers |
US5578073A (en) | 1994-09-16 | 1996-11-26 | Ramot Of Tel Aviv University | Thromboresistant surface treatment for biomaterials |
US5558900A (en) * | 1994-09-22 | 1996-09-24 | Fan; You-Ling | One-step thromboresistant, lubricious coating |
US5485496A (en) | 1994-09-22 | 1996-01-16 | Cornell Research Foundation, Inc. | Gamma irradiation sterilizing of biomaterial medical devices or products, with improved degradation and mechanical properties |
US5649977A (en) | 1994-09-22 | 1997-07-22 | Advanced Cardiovascular Systems, Inc. | Metal reinforced polymer stent |
FR2724938A1 (en) | 1994-09-28 | 1996-03-29 | Lvmh Rech | POLYMERS FUNCTIONALIZED BY AMINO ACIDS OR AMINO ACID DERIVATIVES, THEIR USE AS SURFACTANTS, IN PARTICULAR, IN COSMETIC COMPOSITIONS AND IN PARTICULAR NAIL POLISH. |
ES2155534T3 (en) | 1994-10-12 | 2001-05-16 | Focal Inc | ADMINISTRATION DIRECTED THROUGH BIODEGRADABLE POLYMERS. |
US5637113A (en) | 1994-12-13 | 1997-06-10 | Advanced Cardiovascular Systems, Inc. | Polymer film for wrapping a stent structure |
US5569198A (en) | 1995-01-23 | 1996-10-29 | Cortrak Medical Inc. | Microporous catheter |
US5919570A (en) | 1995-02-01 | 1999-07-06 | Schneider Inc. | Slippery, tenaciously adhering hydrogel coatings containing a polyurethane-urea polymer hydrogel commingled with a poly(N-vinylpyrrolidone) polymer hydrogel, coated polymer and metal substrate materials, and coated medical devices |
US6017577A (en) | 1995-02-01 | 2000-01-25 | Schneider (Usa) Inc. | Slippery, tenaciously adhering hydrophilic polyurethane hydrogel coatings, coated polymer substrate materials, and coated medical devices |
US6231600B1 (en) | 1995-02-22 | 2001-05-15 | Scimed Life Systems, Inc. | Stents with hybrid coating for medical devices |
US5702754A (en) | 1995-02-22 | 1997-12-30 | Meadox Medicals, Inc. | Method of providing a substrate with a hydrophilic coating and substrates, particularly medical devices, provided with such coatings |
US5869127A (en) | 1995-02-22 | 1999-02-09 | Boston Scientific Corporation | Method of providing a substrate with a bio-active/biocompatible coating |
US5854376A (en) | 1995-03-09 | 1998-12-29 | Sekisui Kaseihin Kogyo Kabushiki Kaisha | Aliphatic ester-amide copolymer resins |
US5605696A (en) | 1995-03-30 | 1997-02-25 | Advanced Cardiovascular Systems, Inc. | Drug loaded polymeric material and method of manufacture |
US5837313A (en) | 1995-04-19 | 1998-11-17 | Schneider (Usa) Inc | Drug release stent coating process |
US6120536A (en) | 1995-04-19 | 2000-09-19 | Schneider (Usa) Inc. | Medical devices with long term non-thrombogenic coatings |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
US5925720A (en) | 1995-04-19 | 1999-07-20 | Kazunori Kataoka | Heterotelechelic block copolymers and process for producing the same |
US20020091433A1 (en) | 1995-04-19 | 2002-07-11 | Ni Ding | Drug release coated stent |
US5674242A (en) | 1995-06-06 | 1997-10-07 | Quanam Medical Corporation | Endoprosthetic device with therapeutic compound |
EP0869804A4 (en) | 1995-06-07 | 2001-08-16 | American Nat Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
US6010530A (en) | 1995-06-07 | 2000-01-04 | Boston Scientific Technology, Inc. | Self-expanding endoluminal prosthesis |
AU716005B2 (en) | 1995-06-07 | 2000-02-17 | Cook Medical Technologies Llc | Implantable medical device |
US7611533B2 (en) | 1995-06-07 | 2009-11-03 | Cook Incorporated | Coated implantable medical device |
US5820917A (en) | 1995-06-07 | 1998-10-13 | Medtronic, Inc. | Blood-contacting medical device and method |
WO1998017331A1 (en) | 1995-06-07 | 1998-04-30 | Cook Incorporated | Silver implantable medical device |
US6129761A (en) | 1995-06-07 | 2000-10-10 | Reprogenesis, Inc. | Injectable hydrogel compositions |
US6774278B1 (en) | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
US7550005B2 (en) | 1995-06-07 | 2009-06-23 | Cook Incorporated | Coated implantable medical device |
US5667767A (en) | 1995-07-27 | 1997-09-16 | Micro Therapeutics, Inc. | Compositions for use in embolizing blood vessels |
US5877224A (en) | 1995-07-28 | 1999-03-02 | Rutgers, The State University Of New Jersey | Polymeric drug formulations |
US5723219A (en) | 1995-12-19 | 1998-03-03 | Talison Research | Plasma deposited film networks |
US5658995A (en) | 1995-11-27 | 1997-08-19 | Rutgers, The State University | Copolymers of tyrosine-based polycarbonate and poly(alkylene oxide) |
DE19545678A1 (en) | 1995-12-07 | 1997-06-12 | Goldschmidt Ag Th | Copolymers of polyamino acid esters |
PT1704878E (en) | 1995-12-18 | 2013-07-17 | Angiodevice Internat Gmbh | Crosslinked polymer compositions and methods for their use |
US6033582A (en) | 1996-01-22 | 2000-03-07 | Etex Corporation | Surface modification of medical implants |
US6054553A (en) | 1996-01-29 | 2000-04-25 | Bayer Ag | Process for the preparation of polymers having recurring agents |
GB9606452D0 (en) | 1996-03-27 | 1996-06-05 | Sandoz Ltd | Organic compounds |
US5932299A (en) | 1996-04-23 | 1999-08-03 | Katoot; Mohammad W. | Method for modifying the surface of an object |
US5955509A (en) | 1996-05-01 | 1999-09-21 | Board Of Regents, The University Of Texas System | pH dependent polymer micelles |
US5610241A (en) | 1996-05-07 | 1997-03-11 | Cornell Research Foundation, Inc. | Reactive graft polymer with biodegradable polymer backbone and method for preparing reactive biodegradable polymers |
DK0914102T3 (en) | 1996-05-24 | 2006-01-09 | Angiotech Pharm Inc | Preparations and methods for treating or preventing diseases of the body canals |
US5670161A (en) | 1996-05-28 | 1997-09-23 | Healy; Kevin E. | Biodegradable stent |
US5876433A (en) | 1996-05-29 | 1999-03-02 | Ethicon, Inc. | Stent and method of varying amounts of heparin coated thereon to control treatment |
US5874165A (en) | 1996-06-03 | 1999-02-23 | Gore Enterprise Holdings, Inc. | Materials and method for the immobilization of bioactive species onto polymeric subtrates |
NL1003459C2 (en) | 1996-06-28 | 1998-01-07 | Univ Twente | Copoly (ester amides) and copoly (ester urethanes). |
US5711958A (en) | 1996-07-11 | 1998-01-27 | Life Medical Sciences, Inc. | Methods for reducing or eliminating post-surgical adhesion formation |
US5830178A (en) | 1996-10-11 | 1998-11-03 | Micro Therapeutics, Inc. | Methods for embolizing vascular sites with an emboilizing composition comprising dimethylsulfoxide |
PT956034E (en) | 1996-07-30 | 2002-12-31 | Novartis Ag | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF TRANSPLANT REJECTION OF INFLAMMATORY OR AUTO-IMMUNE STATES COMPOSING CYCOSPORINE E 40-O- (2-HYDROXYETHYL) -RAPAMICINE |
US6060518A (en) | 1996-08-16 | 2000-05-09 | Supratek Pharma Inc. | Polymer compositions for chemotherapy and methods of treatment using the same |
US6030371A (en) * | 1996-08-23 | 2000-02-29 | Pursley; Matt D. | Catheters and method for nonextrusion manufacturing of catheters |
AU4090997A (en) | 1996-08-30 | 1998-03-19 | Helix Medical Corporation | Medical devices having microbial resistant material properties |
US5783657A (en) | 1996-10-18 | 1998-07-21 | Union Camp Corporation | Ester-terminated polyamides of polymerized fatty acids useful in formulating transparent gels in low polarity liquids |
US6530951B1 (en) | 1996-10-24 | 2003-03-11 | Cook Incorporated | Silver implantable medical device |
US6120491A (en) | 1997-11-07 | 2000-09-19 | The State University Rutgers | Biodegradable, anionic polymers derived from the amino acid L-tyrosine |
US5980972A (en) | 1996-12-20 | 1999-11-09 | Schneider (Usa) Inc | Method of applying drug-release coatings |
US5997517A (en) | 1997-01-27 | 1999-12-07 | Sts Biopolymers, Inc. | Bonding layers for medical device surface coatings |
WO1998032777A1 (en) | 1997-01-28 | 1998-07-30 | United States Surgical Corporation | Polyesteramides with amino acid-derived groups alternating with alpha-hydroxyacid-derived groups and surgical articles made therefrom |
EP0960148B1 (en) | 1997-01-28 | 2003-04-02 | United States Surgical Corporation | Polyesteramide, its preparation and surgical devices fabricated therefrom |
AU5932198A (en) | 1997-01-28 | 1998-08-18 | United States Surgical Corporation | Polyesteramide, its preparation and surgical devices fabricated therefrom |
KR100526913B1 (en) | 1997-02-20 | 2005-11-09 | 쿡 인코포레이티드 | Coated implantable medical device |
US6240616B1 (en) | 1997-04-15 | 2001-06-05 | Advanced Cardiovascular Systems, Inc. | Method of manufacturing a medicated porous metal prosthesis |
US6273913B1 (en) | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
US5879697A (en) | 1997-04-30 | 1999-03-09 | Schneider Usa Inc | Drug-releasing coatings for medical devices |
US6180632B1 (en) | 1997-05-28 | 2001-01-30 | Aventis Pharmaceuticals Products Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
US6159978A (en) | 1997-05-28 | 2000-12-12 | Aventis Pharmaceuticals Product, Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
US6245760B1 (en) | 1997-05-28 | 2001-06-12 | Aventis Pharmaceuticals Products, Inc | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
US6056993A (en) | 1997-05-30 | 2000-05-02 | Schneider (Usa) Inc. | Porous protheses and methods for making the same wherein the protheses are formed by spraying water soluble and water insoluble fibers onto a rotating mandrel |
US6110483A (en) | 1997-06-23 | 2000-08-29 | Sts Biopolymers, Inc. | Adherent, flexible hydrogel and medicated coatings |
KR20010020611A (en) | 1997-07-01 | 2001-03-15 | 아테로제닉스, 인코포레이티드 | Antioxidant enhancement of therapy for hyperproliferative conditions |
US6211249B1 (en) | 1997-07-11 | 2001-04-03 | Life Medical Sciences, Inc. | Polyester polyether block copolymers |
US5891507A (en) | 1997-07-28 | 1999-04-06 | Iowa-India Investments Company Limited | Process for coating a surface of a metallic stent |
US5980928A (en) | 1997-07-29 | 1999-11-09 | Terry; Paul B. | Implant for preventing conjunctivitis in cattle |
CA2298580A1 (en) | 1997-08-08 | 1999-02-18 | The Procter & Gamble Company | Laundry detergent compositions with amino acid based polymers to provide appearance and integrity benefits to fabrics laundered therewith |
US6121027A (en) | 1997-08-15 | 2000-09-19 | Surmodics, Inc. | Polybifunctional reagent having a polymeric backbone and photoreactive moieties and bioactive groups |
US6242063B1 (en) * | 1997-09-10 | 2001-06-05 | Scimed Life Systems, Inc. | Balloons made from liquid crystal polymer blends |
US6120788A (en) | 1997-10-16 | 2000-09-19 | Bioamide, Inc. | Bioabsorbable triglycolic acid poly(ester-amide)s |
US6015541A (en) | 1997-11-03 | 2000-01-18 | Micro Therapeutics, Inc. | Radioactive embolizing compositions |
US6221425B1 (en) | 1998-01-30 | 2001-04-24 | Advanced Cardiovascular Systems, Inc. | Lubricious hydrophilic coating for an intracorporeal medical device |
US6110188A (en) | 1998-03-09 | 2000-08-29 | Corvascular, Inc. | Anastomosis method |
US6258371B1 (en) | 1998-04-03 | 2001-07-10 | Medtronic Inc | Method for making biocompatible medical article |
US20030040790A1 (en) | 1998-04-15 | 2003-02-27 | Furst Joseph G. | Stent coating |
US20010029351A1 (en) | 1998-04-16 | 2001-10-11 | Robert Falotico | Drug combinations and delivery devices for the prevention and treatment of vascular disease |
US7658727B1 (en) | 1998-04-20 | 2010-02-09 | Medtronic, Inc | Implantable medical device with enhanced biocompatibility and biostability |
US20020188037A1 (en) | 1999-04-15 | 2002-12-12 | Chudzik Stephen J. | Method and system for providing bioactive agent release coating |
CA2320259C (en) | 1998-04-27 | 2006-01-24 | Surmodics, Inc. | Bioactive agent release coating |
US6113629A (en) | 1998-05-01 | 2000-09-05 | Micrus Corporation | Hydrogel for the therapeutic treatment of aneurysms |
KR100314496B1 (en) | 1998-05-28 | 2001-11-22 | 윤동진 | Non-thrombogenic heparin derivatives, process for preparation and use thereof |
US6281225B1 (en) | 1998-06-11 | 2001-08-28 | Cerus Corporation | Inhibiting proliferation of arterial smooth muscle cells |
AU4645299A (en) | 1998-07-08 | 2000-02-01 | Advanced Biocompatible Coatings Inc. | Biocompatible metallic stents with hydroxy methacrylate coating |
US6156064A (en) * | 1998-08-14 | 2000-12-05 | Schneider (Usa) Inc | Stent-graft-membrane and method of making the same |
CA2340652C (en) | 1998-08-20 | 2013-09-24 | Cook Incorporated | Coated implantable medical device comprising paclitaxel |
US6248127B1 (en) | 1998-08-21 | 2001-06-19 | Medtronic Ave, Inc. | Thromboresistant coated medical device |
US6335029B1 (en) | 1998-08-28 | 2002-01-01 | Scimed Life Systems, Inc. | Polymeric coatings for controlled delivery of active agents |
WO2000012147A1 (en) | 1998-09-02 | 2000-03-09 | Scimed Life Systems, Inc. | Drug delivery device for stent |
US6011125A (en) | 1998-09-25 | 2000-01-04 | General Electric Company | Amide modified polyesters |
WO2000018446A1 (en) | 1998-09-25 | 2000-04-06 | Cathnet-Science S.A. | Multi-layered sleeve for intravascular expandable device |
US6613363B1 (en) * | 1998-10-02 | 2003-09-02 | Wm. Wrigley Jr. Company | Biodegradable chewing gum bases including plasticized poly(D,L-lactic acid) and copolymers thereof |
US6358567B2 (en) | 1998-12-23 | 2002-03-19 | The Regents Of The University Of California | Colloidal spray method for low cost thin coating deposition |
US6530950B1 (en) | 1999-01-12 | 2003-03-11 | Quanam Medical Corporation | Intraluminal stent having coaxial polymer member |
US6419692B1 (en) | 1999-02-03 | 2002-07-16 | Scimed Life Systems, Inc. | Surface protection method for stents and balloon catheters for drug delivery |
US6143354A (en) | 1999-02-08 | 2000-11-07 | Medtronic Inc. | One-step method for attachment of biomolecules to substrate surfaces |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US6364903B2 (en) * | 1999-03-19 | 2002-04-02 | Meadox Medicals, Inc. | Polymer coated stent |
US6368658B1 (en) | 1999-04-19 | 2002-04-09 | Scimed Life Systems, Inc. | Coating medical devices using air suspension |
AU4975500A (en) | 1999-04-23 | 2000-11-10 | Agion Technologies, Llc | Stent having antimicrobial agent |
US6156373A (en) * | 1999-05-03 | 2000-12-05 | Scimed Life Systems, Inc. | Medical device coating methods and devices |
US6258121B1 (en) | 1999-07-02 | 2001-07-10 | Scimed Life Systems, Inc. | Stent coating |
US6494862B1 (en) | 1999-07-13 | 2002-12-17 | Advanced Cardiovascular Systems, Inc. | Substance delivery apparatus and a method of delivering a therapeutic substance to an anatomical passageway |
US6283947B1 (en) | 1999-07-13 | 2001-09-04 | Advanced Cardiovascular Systems, Inc. | Local drug delivery injection catheter |
US6177523B1 (en) | 1999-07-14 | 2001-01-23 | Cardiotech International, Inc. | Functionalized polyurethanes |
FI19991852A (en) | 1999-09-01 | 2001-03-01 | Yli Urpo Antti | New multilayer material with a biologically active agent, and its preparation |
US6790228B2 (en) | 1999-12-23 | 2004-09-14 | Advanced Cardiovascular Systems, Inc. | Coating for implantable devices and a method of forming the same |
DE60032912T2 (en) | 1999-09-03 | 2007-10-25 | Advanced Cardiovascular Systems, Inc., Santa Clara | POROUS PROSTHESIS AND METHOD FOR THE DEPOSITION OF SUBSTANCES IN THE PORES |
US7807211B2 (en) * | 1999-09-03 | 2010-10-05 | Advanced Cardiovascular Systems, Inc. | Thermal treatment of an implantable medical device |
US6749626B1 (en) | 2000-03-31 | 2004-06-15 | Advanced Cardiovascular Systems, Inc. | Actinomycin D for the treatment of vascular disease |
US6379381B1 (en) | 1999-09-03 | 2002-04-30 | Advanced Cardiovascular Systems, Inc. | Porous prosthesis and a method of depositing substances into the pores |
US6503556B2 (en) | 2000-12-28 | 2003-01-07 | Advanced Cardiovascular Systems, Inc. | Methods of forming a coating for a prosthesis |
US6287628B1 (en) | 1999-09-03 | 2001-09-11 | Advanced Cardiovascular Systems, Inc. | Porous prosthesis and a method of depositing substances into the pores |
US6713119B2 (en) | 1999-09-03 | 2004-03-30 | Advanced Cardiovascular Systems, Inc. | Biocompatible coating for a prosthesis and a method of forming the same |
US6503954B1 (en) | 2000-03-31 | 2003-01-07 | Advanced Cardiovascular Systems, Inc. | Biocompatible carrier containing actinomycin D and a method of forming the same |
US20040029952A1 (en) | 1999-09-03 | 2004-02-12 | Yung-Ming Chen | Ethylene vinyl alcohol composition and coating |
US6759054B2 (en) | 1999-09-03 | 2004-07-06 | Advanced Cardiovascular Systems, Inc. | Ethylene vinyl alcohol composition and coating |
US20070032853A1 (en) | 2002-03-27 | 2007-02-08 | Hossainy Syed F | 40-O-(2-hydroxy)ethyl-rapamycin coated stent |
US6203551B1 (en) | 1999-10-04 | 2001-03-20 | Advanced Cardiovascular Systems, Inc. | Chamber for applying therapeutic substances to an implant device |
US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
US6251136B1 (en) | 1999-12-08 | 2001-06-26 | Advanced Cardiovascular Systems, Inc. | Method of layering a three-coated stent using pharmacological and polymeric agents |
US6613432B2 (en) | 1999-12-22 | 2003-09-02 | Biosurface Engineering Technologies, Inc. | Plasma-deposited coatings, devices and methods |
US6908624B2 (en) | 1999-12-23 | 2005-06-21 | Advanced Cardiovascular Systems, Inc. | Coating for implantable devices and a method of forming the same |
US6283949B1 (en) | 1999-12-27 | 2001-09-04 | Advanced Cardiovascular Systems, Inc. | Refillable implantable drug delivery pump |
AU2599501A (en) | 1999-12-29 | 2001-07-09 | Advanced Cardiovascular Systems Inc. | Device and active component for inhibiting formation of thrombus-inflammatory cell matrix |
US6899731B2 (en) | 1999-12-30 | 2005-05-31 | Boston Scientific Scimed, Inc. | Controlled delivery of therapeutic agents by insertable medical devices |
JP4473390B2 (en) | 2000-01-07 | 2010-06-02 | 川澄化学工業株式会社 | Stent and stent graft |
ATE280499T1 (en) | 2000-01-11 | 2004-11-15 | Intralytix Inc | METHOD AND DEVICE FOR CLEANING WITH BACTERIOPHAGES |
US6527801B1 (en) | 2000-04-13 | 2003-03-04 | Advanced Cardiovascular Systems, Inc. | Biodegradable drug delivery material for stent |
US20020007215A1 (en) | 2000-05-19 | 2002-01-17 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US20020005206A1 (en) | 2000-05-19 | 2002-01-17 | Robert Falotico | Antiproliferative drug and delivery device |
US6776796B2 (en) | 2000-05-12 | 2004-08-17 | Cordis Corportation | Antiinflammatory drug and delivery device |
US20020007213A1 (en) | 2000-05-19 | 2002-01-17 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US20020007214A1 (en) | 2000-05-19 | 2002-01-17 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
DK1301221T3 (en) | 2000-05-16 | 2006-07-03 | Ortho Mcneil Pharm Inc | Method of coating medical articles using supercritical carbon dioxide |
US6673385B1 (en) | 2000-05-31 | 2004-01-06 | Advanced Cardiovascular Systems, Inc. | Methods for polymeric coatings stents |
US6395326B1 (en) | 2000-05-31 | 2002-05-28 | Advanced Cardiovascular Systems, Inc. | Apparatus and method for depositing a coating onto a surface of a prosthesis |
US6585765B1 (en) | 2000-06-29 | 2003-07-01 | Advanced Cardiovascular Systems, Inc. | Implantable device having substances impregnated therein and a method of impregnating the same |
US20020077693A1 (en) | 2000-12-19 | 2002-06-20 | Barclay Bruce J. | Covered, coiled drug delivery stent and method |
AU2001279288A1 (en) | 2000-07-06 | 2002-01-21 | Biosurface Engineering Technologies, Inc. | Drug diffusion coatings, applications and methods |
GB2365127A (en) | 2000-07-20 | 2002-02-13 | Jomed Imaging Ltd | Catheter |
US6555157B1 (en) | 2000-07-25 | 2003-04-29 | Advanced Cardiovascular Systems, Inc. | Method for coating an implantable device and system for performing the method |
WO2002009768A2 (en) | 2000-07-27 | 2002-02-07 | Rutgers, The State University | Therapeutic polyesters and polyamides |
US6534112B1 (en) * | 2000-08-01 | 2003-03-18 | Ams Research Corporation | Semi-automatic coating system methods for coating medical devices |
US6451373B1 (en) | 2000-08-04 | 2002-09-17 | Advanced Cardiovascular Systems, Inc. | Method of forming a therapeutic coating onto a surface of an implantable prosthesis |
US6503538B1 (en) | 2000-08-30 | 2003-01-07 | Cornell Research Foundation, Inc. | Elastomeric functional biodegradable copolyester amides and copolyester urethanes |
US6585926B1 (en) | 2000-08-31 | 2003-07-01 | Advanced Cardiovascular Systems, Inc. | Method of manufacturing a porous balloon |
WO2002026162A2 (en) | 2000-09-26 | 2002-04-04 | Advanced Cardiovascular Systems, Inc. | A method of loading a substance onto an implantable device |
US6716444B1 (en) | 2000-09-28 | 2004-04-06 | Advanced Cardiovascular Systems, Inc. | Barriers for polymer-coated implantable medical devices and methods for making the same |
US6254632B1 (en) | 2000-09-28 | 2001-07-03 | Advanced Cardiovascular Systems, Inc. | Implantable medical device having protruding surface structures for drug delivery and cover attachment |
DK1335761T3 (en) * | 2000-09-29 | 2008-02-04 | Ethicon Inc | Coatings for medical devices |
US6746773B2 (en) | 2000-09-29 | 2004-06-08 | Ethicon, Inc. | Coatings for medical devices |
US20020051730A1 (en) | 2000-09-29 | 2002-05-02 | Stanko Bodnar | Coated medical devices and sterilization thereof |
US7261735B2 (en) | 2001-05-07 | 2007-08-28 | Cordis Corporation | Local drug delivery devices and methods for maintaining the drug coatings thereon |
US20020111590A1 (en) | 2000-09-29 | 2002-08-15 | Davila Luis A. | Medical devices, drug coatings and methods for maintaining the drug coatings thereon |
US6506437B1 (en) | 2000-10-17 | 2003-01-14 | Advanced Cardiovascular Systems, Inc. | Methods of coating an implantable device having depots formed in a surface thereof |
US6783793B1 (en) | 2000-10-26 | 2004-08-31 | Advanced Cardiovascular Systems, Inc. | Selective coating of medical devices |
US6558733B1 (en) | 2000-10-26 | 2003-05-06 | Advanced Cardiovascular Systems, Inc. | Method for etching a micropatterned microdepot prosthesis |
US6758859B1 (en) | 2000-10-30 | 2004-07-06 | Kenny L. Dang | Increased drug-loading and reduced stress drug delivery device |
US6545097B2 (en) | 2000-12-12 | 2003-04-08 | Scimed Life Systems, Inc. | Drug delivery compositions and medical devices containing block copolymer |
US6824559B2 (en) | 2000-12-22 | 2004-11-30 | Advanced Cardiovascular Systems, Inc. | Ethylene-carboxyl copolymers as drug delivery matrices |
EP1355588B1 (en) | 2000-12-22 | 2007-08-15 | Avantec Vascular Corporation | Device for delivery of therepeutic agents |
US7077859B2 (en) | 2000-12-22 | 2006-07-18 | Avantec Vascular Corporation | Apparatus and methods for variably controlled substance delivery from implanted prostheses |
US20020082679A1 (en) | 2000-12-22 | 2002-06-27 | Avantec Vascular Corporation | Delivery or therapeutic capable agents |
US6544543B1 (en) | 2000-12-27 | 2003-04-08 | Advanced Cardiovascular Systems, Inc. | Periodic constriction of vessels to treat ischemic tissue |
US6540776B2 (en) | 2000-12-28 | 2003-04-01 | Advanced Cardiovascular Systems, Inc. | Sheath for a prosthesis and methods of forming the same |
US6663662B2 (en) | 2000-12-28 | 2003-12-16 | Advanced Cardiovascular Systems, Inc. | Diffusion barrier layer for implantable devices |
US20020087123A1 (en) | 2001-01-02 | 2002-07-04 | Hossainy Syed F.A. | Adhesion of heparin-containing coatings to blood-contacting surfaces of medical devices |
US6544582B1 (en) | 2001-01-05 | 2003-04-08 | Advanced Cardiovascular Systems, Inc. | Method and apparatus for coating an implantable device |
US6645195B1 (en) | 2001-01-05 | 2003-11-11 | Advanced Cardiovascular Systems, Inc. | Intraventricularly guided agent delivery system and method of use |
US6544223B1 (en) | 2001-01-05 | 2003-04-08 | Advanced Cardiovascular Systems, Inc. | Balloon catheter for delivering therapeutic agents |
US6740040B1 (en) | 2001-01-30 | 2004-05-25 | Advanced Cardiovascular Systems, Inc. | Ultrasound energy driven intraventricular catheter to treat ischemia |
US20030032767A1 (en) | 2001-02-05 | 2003-02-13 | Yasuhiro Tada | High-strength polyester-amide fiber and process for producing the same |
AU2002238076B2 (en) | 2001-02-09 | 2007-05-17 | Endoluminal Therapeutics, Inc. | Endomural therapy |
US20030004141A1 (en) | 2001-03-08 | 2003-01-02 | Brown David L. | Medical devices, compositions and methods for treating vulnerable plaque |
US6780424B2 (en) | 2001-03-30 | 2004-08-24 | Charles David Claude | Controlled morphologies in polymer drug for release of drugs from polymer films |
US6645135B1 (en) | 2001-03-30 | 2003-11-11 | Advanced Cardiovascular Systems, Inc. | Intravascular catheter device and method for simultaneous local delivery of radiation and a therapeutic substance |
US6623448B2 (en) | 2001-03-30 | 2003-09-23 | Advanced Cardiovascular Systems, Inc. | Steerable drug delivery device |
US6625486B2 (en) | 2001-04-11 | 2003-09-23 | Advanced Cardiovascular Systems, Inc. | Method and apparatus for intracellular delivery of an agent |
US6764505B1 (en) | 2001-04-12 | 2004-07-20 | Advanced Cardiovascular Systems, Inc. | Variable surface area stent |
US7056339B2 (en) | 2001-04-20 | 2006-06-06 | The Board Of Trustees Of The Leland Stanford Junior University | Drug delivery platform |
US6712845B2 (en) | 2001-04-24 | 2004-03-30 | Advanced Cardiovascular Systems, Inc. | Coating for a stent and a method of forming the same |
WO2002087586A1 (en) | 2001-04-26 | 2002-11-07 | Control Delivery Systems, Inc. | Sustained release drug delivery system containing codrugs |
US6660034B1 (en) | 2001-04-30 | 2003-12-09 | Advanced Cardiovascular Systems, Inc. | Stent for increasing blood flow to ischemic tissues and a method of using the same |
US6656506B1 (en) | 2001-05-09 | 2003-12-02 | Advanced Cardiovascular Systems, Inc. | Microparticle coated medical device |
US7651695B2 (en) | 2001-05-18 | 2010-01-26 | Advanced Cardiovascular Systems, Inc. | Medicated stents for the treatment of vascular disease |
US6605154B1 (en) | 2001-05-31 | 2003-08-12 | Advanced Cardiovascular Systems, Inc. | Stent mounting device |
US6743462B1 (en) | 2001-05-31 | 2004-06-01 | Advanced Cardiovascular Systems, Inc. | Apparatus and method for coating implantable devices |
US7862495B2 (en) | 2001-05-31 | 2011-01-04 | Advanced Cardiovascular Systems, Inc. | Radiation or drug delivery source with activity gradient to minimize edge effects |
US6666880B1 (en) | 2001-06-19 | 2003-12-23 | Advised Cardiovascular Systems, Inc. | Method and system for securing a coated stent to a balloon catheter |
US6572644B1 (en) | 2001-06-27 | 2003-06-03 | Advanced Cardiovascular Systems, Inc. | Stent mounting device and a method of using the same to coat a stent |
US7247313B2 (en) | 2001-06-27 | 2007-07-24 | Advanced Cardiovascular Systems, Inc. | Polyacrylates coatings for implantable medical devices |
US6695920B1 (en) | 2001-06-27 | 2004-02-24 | Advanced Cardiovascular Systems, Inc. | Mandrel for supporting a stent and a method of using the mandrel to coat a stent |
US8741378B1 (en) * | 2001-06-27 | 2014-06-03 | Advanced Cardiovascular Systems, Inc. | Methods of coating an implantable device |
US6565659B1 (en) | 2001-06-28 | 2003-05-20 | Advanced Cardiovascular Systems, Inc. | Stent mounting assembly and a method of using the same to coat a stent |
US6673154B1 (en) | 2001-06-28 | 2004-01-06 | Advanced Cardiovascular Systems, Inc. | Stent mounting device to coat a stent |
US6585755B2 (en) | 2001-06-29 | 2003-07-01 | Advanced Cardiovascular | Polymeric stent suitable for imaging by MRI and fluoroscopy |
US6706013B1 (en) | 2001-06-29 | 2004-03-16 | Advanced Cardiovascular Systems, Inc. | Variable length drug delivery catheter |
US6527863B1 (en) | 2001-06-29 | 2003-03-04 | Advanced Cardiovascular Systems, Inc. | Support device for a stent and a method of using the same to coat a stent |
US6656216B1 (en) | 2001-06-29 | 2003-12-02 | Advanced Cardiovascular Systems, Inc. | Composite stent with regioselective material |
EP1273314A1 (en) | 2001-07-06 | 2003-01-08 | Terumo Kabushiki Kaisha | Stent |
US6641611B2 (en) | 2001-11-26 | 2003-11-04 | Swaminathan Jayaraman | Therapeutic coating for an intravascular implant |
US8303651B1 (en) | 2001-09-07 | 2012-11-06 | Advanced Cardiovascular Systems, Inc. | Polymeric coating for reducing the rate of release of a therapeutic substance from a stent |
US7285304B1 (en) * | 2003-06-25 | 2007-10-23 | Advanced Cardiovascular Systems, Inc. | Fluid treatment of a polymeric coating on an implantable medical device |
WO2003028590A1 (en) | 2001-09-24 | 2003-04-10 | Medtronic Ave Inc. | Rational drug therapy device and methods |
US7195640B2 (en) | 2001-09-25 | 2007-03-27 | Cordis Corporation | Coated medical devices for the treatment of vulnerable plaque |
US20030059520A1 (en) | 2001-09-27 | 2003-03-27 | Yung-Ming Chen | Apparatus for regulating temperature of a composition and a method of coating implantable devices |
US6753071B1 (en) | 2001-09-27 | 2004-06-22 | Advanced Cardiovascular Systems, Inc. | Rate-reducing membrane for release of an agent |
US20030073961A1 (en) | 2001-09-28 | 2003-04-17 | Happ Dorrie M. | Medical device containing light-protected therapeutic agent and a method for fabricating thereof |
US20030065377A1 (en) | 2001-09-28 | 2003-04-03 | Davila Luis A. | Coated medical devices |
US7524528B2 (en) * | 2001-10-05 | 2009-04-28 | Cabot Corporation | Precursor compositions and methods for the deposition of passive electrical components on a substrate |
US6939376B2 (en) | 2001-11-05 | 2005-09-06 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
US7682387B2 (en) | 2002-04-24 | 2010-03-23 | Biosensors International Group, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
CA2466432A1 (en) | 2001-11-08 | 2003-05-15 | Atrium Medical Corporation | Intraluminal device with a coating containing a therapeutic agent |
US7585516B2 (en) | 2001-11-12 | 2009-09-08 | Advanced Cardiovascular Systems, Inc. | Coatings for drug delivery devices |
US6663880B1 (en) | 2001-11-30 | 2003-12-16 | Advanced Cardiovascular Systems, Inc. | Permeabilizing reagents to increase drug delivery and a method of local delivery |
US6709514B1 (en) | 2001-12-28 | 2004-03-23 | Advanced Cardiovascular Systems, Inc. | Rotary coating apparatus for coating implantable medical devices |
US20060093771A1 (en) * | 2002-02-15 | 2006-05-04 | Frantisek Rypacek | Polymer coating for medical devices |
AU2003225882A1 (en) | 2002-03-20 | 2003-10-08 | Advanced Cardiovascular Systems, Inc. | Biodegradable hydrophobic polymer for stents |
US7166133B2 (en) * | 2002-06-13 | 2007-01-23 | Kensey Nash Corporation | Devices and methods for treating defects in the tissue of a living being |
US7491233B1 (en) | 2002-07-19 | 2009-02-17 | Advanced Cardiovascular Systems Inc. | Purified polymers for coatings of implantable medical devices |
US20040054104A1 (en) | 2002-09-05 | 2004-03-18 | Pacetti Stephen D. | Coatings for drug delivery devices comprising modified poly(ethylene-co-vinyl alcohol) |
AU2003275190A1 (en) | 2002-09-18 | 2004-04-08 | Medtronic Vascular, Inc. | Controllable drug releasing gradient coatings for medical devices |
US20040063805A1 (en) | 2002-09-19 | 2004-04-01 | Pacetti Stephen D. | Coatings for implantable medical devices and methods for fabrication thereof |
US7087263B2 (en) | 2002-10-09 | 2006-08-08 | Advanced Cardiovascular Systems, Inc. | Rare limiting barriers for implantable medical devices |
US20040167572A1 (en) * | 2003-02-20 | 2004-08-26 | Roth Noah M. | Coated medical devices |
US8715771B2 (en) | 2003-02-26 | 2014-05-06 | Abbott Cardiovascular Systems Inc. | Coated stent and method of making the same |
WO2004087045A2 (en) | 2003-03-28 | 2004-10-14 | Kosan Biosciences, Inc. | Devices, methods, and compositions to prevent restenosis |
US7431959B1 (en) * | 2003-07-31 | 2008-10-07 | Advanced Cardiovascular Systems Inc. | Method and system for irradiation of a drug eluting implantable medical device |
US7309232B2 (en) * | 2003-10-10 | 2007-12-18 | Dentigenix Inc. | Methods for treating dental conditions using tissue scaffolds |
US7220755B2 (en) | 2003-11-12 | 2007-05-22 | Biosensors International Group, Ltd. | 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same |
US20050112170A1 (en) | 2003-11-20 | 2005-05-26 | Hossainy Syed F. | Coatings for implantable devices comprising polymers of lactic acid and methods for fabricating the same |
EP1699503B8 (en) | 2003-12-24 | 2012-11-07 | Novartis AG | Devices coated with PEC polymers |
US7901451B2 (en) | 2004-09-24 | 2011-03-08 | Biosensors International Group, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
AU2006231652A1 (en) | 2005-04-05 | 2006-10-12 | Elixir Medical Corporation | Degradable implantable medical devices |
US8778375B2 (en) * | 2005-04-29 | 2014-07-15 | Advanced Cardiovascular Systems, Inc. | Amorphous poly(D,L-lactide) coating |
US7655584B2 (en) * | 2005-07-29 | 2010-02-02 | Gore Enterprise Holdings, Inc. | Highly porous self-cohered web materials |
US20070155010A1 (en) * | 2005-07-29 | 2007-07-05 | Farnsworth Ted R | Highly porous self-cohered fibrous tissue engineering scaffold |
US20080091262A1 (en) * | 2006-10-17 | 2008-04-17 | Gale David C | Drug delivery after biodegradation of the stent scaffolding |
US8952123B1 (en) * | 2006-08-02 | 2015-02-10 | Abbott Cardiovascular Systems Inc. | Dioxanone-based copolymers for implantable devices |
US8088789B2 (en) | 2006-09-13 | 2012-01-03 | Elixir Medical Corporation | Macrocyclic lactone compounds and methods for their use |
EP2083834B1 (en) | 2006-09-13 | 2017-06-21 | Elixir Medical Corporation | Macrocyclic lactone compounds and methods for their use |
WO2008051867A2 (en) | 2006-10-20 | 2008-05-02 | Elixir Medical Corporation | Luminal prostheses and methods for coating thereof |
US20080177373A1 (en) | 2007-01-19 | 2008-07-24 | Elixir Medical Corporation | Endoprosthesis structures having supporting features |
US20130150943A1 (en) | 2007-01-19 | 2013-06-13 | Elixir Medical Corporation | Biodegradable endoprostheses and methods for their fabrication |
US8814930B2 (en) * | 2007-01-19 | 2014-08-26 | Elixir Medical Corporation | Biodegradable endoprosthesis and methods for their fabrication |
US8961589B2 (en) | 2007-08-01 | 2015-02-24 | Abbott Cardiovascular Systems Inc. | Bioabsorbable coating with tunable hydrophobicity |
US8661630B2 (en) * | 2008-05-21 | 2014-03-04 | Abbott Cardiovascular Systems Inc. | Coating comprising an amorphous primer layer and a semi-crystalline reservoir layer |
US20090110713A1 (en) * | 2007-10-31 | 2009-04-30 | Florencia Lim | Biodegradable polymeric materials providing controlled release of hydrophobic drugs from implantable devices |
US8057876B2 (en) | 2008-02-25 | 2011-11-15 | Abbott Cardiovascular Systems Inc. | Bioabsorbable stent with layers having different degradation rates |
EP2296578A4 (en) | 2008-06-12 | 2014-01-15 | Elixir Medical Corp | Intravascular stent |
US20100055145A1 (en) | 2008-08-29 | 2010-03-04 | Biosensors International Group | Stent coatings for reducing late stent thrombosis |
WO2010040064A1 (en) | 2008-10-03 | 2010-04-08 | Elixir Medical Corporation | Macrocyclic lactone compounds and methods for their use |
EP2411440B1 (en) * | 2009-03-23 | 2018-01-17 | Micell Technologies, Inc. | Improved biodegradable polymers |
US8697110B2 (en) * | 2009-05-14 | 2014-04-15 | Abbott Cardiovascular Systems Inc. | Polymers comprising amorphous terpolymers and semicrystalline blocks |
EP2498835B1 (en) * | 2009-11-13 | 2017-05-24 | Nanyang Technological University | Biodegradable thermoplastic elastomers |
US8685433B2 (en) | 2010-03-31 | 2014-04-01 | Abbott Cardiovascular Systems Inc. | Absorbable coating for implantable device |
EP2624834A4 (en) | 2010-10-04 | 2014-09-17 | Elixir Medical Corp | Macrocyclic lactone compounds and methods for their use |
US8840678B2 (en) * | 2012-02-10 | 2014-09-23 | Abbott Cardiovascular Systems Inc. | Drug-eluting bioabsorbable renal artery stent for renal cancer and inflammatory disorders |
CN104587534A (en) * | 2013-10-31 | 2015-05-06 | 先健科技(深圳)有限公司 | An absorbable iron-base alloy support |
JP2017505817A (en) * | 2014-02-04 | 2017-02-23 | アボット カーディオバスキュラー システムズ インコーポレイテッド | Drug delivery scaffold or stent having a coating based on NOVOLIMUS and lactide so that the binding of NOVOLIMUS to the coating is minimized |
US9855371B2 (en) * | 2014-04-28 | 2018-01-02 | John James Scanlon | Bioresorbable stent |
CN107155299A (en) * | 2014-06-02 | 2017-09-12 | 阿玛安斯医药私人公司 | Bioabsorbable support |
-
2004
- 2004-12-23 US US11/022,228 patent/US8741378B1/en not_active Expired - Fee Related
-
2014
- 2014-04-23 US US14/259,458 patent/US20150030654A1/en not_active Abandoned
-
2015
- 2015-08-21 US US14/832,889 patent/US10064982B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6096070A (en) * | 1995-06-07 | 2000-08-01 | Med Institute Inc. | Coated implantable medical device |
US6153252A (en) * | 1998-06-30 | 2000-11-28 | Ethicon, Inc. | Process for coating stents |
US20030219562A1 (en) * | 2002-02-15 | 2003-11-27 | Frantisek Rypacek | Polymer coating for medical devices |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018204289A1 (en) * | 2017-05-01 | 2018-11-08 | 480 Biomedical, Inc. | Drug-eluting medical implants |
US10201639B2 (en) * | 2017-05-01 | 2019-02-12 | 480 Biomedical, Inc. | Drug-eluting medical implants |
Also Published As
Publication number | Publication date |
---|---|
US20150359943A1 (en) | 2015-12-17 |
US10064982B2 (en) | 2018-09-04 |
US8741378B1 (en) | 2014-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7504125B1 (en) | System and method for coating implantable devices | |
US7763308B2 (en) | Method of regulating temperature of a composition for coating implantable medical devices | |
US8551446B2 (en) | Poly(vinyl acetal) coatings for implantable medical devices | |
US8303651B1 (en) | Polymeric coating for reducing the rate of release of a therapeutic substance from a stent | |
US6753071B1 (en) | Rate-reducing membrane for release of an agent | |
US7335391B1 (en) | Method for coating implantable devices | |
US7063884B2 (en) | Stent coating | |
US6926919B1 (en) | Method for fabricating a coating for a medical device | |
US9180227B2 (en) | Coating layers for medical devices and method of making the same | |
US7396539B1 (en) | Stent coatings with engineered drug release rate | |
US7087263B2 (en) | Rare limiting barriers for implantable medical devices | |
US7563483B2 (en) | Methods for fabricating a coating for implantable medical devices | |
US10064982B2 (en) | PDLLA stent coating | |
US20070281073A1 (en) | Enhanced adhesion of drug delivery coatings on stents | |
US7824729B2 (en) | Methods for coating an implantable device | |
US8980364B2 (en) | Method of drying bioabsorbable coating over stents | |
US7645504B1 (en) | Coatings for implantable medical devices comprising hydrophobic and hydrophilic polymers | |
US7481835B1 (en) | Encapsulated covered stent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |